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ABSTRACT OF THE DISSERTATION
Genetic and Cellular Studies of the Podocyte in Focal Segmental Glomerulosclerosis
by
Haiyang Yu
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular and Cellular Biology
Washington University in St. Louis, 2015
Professor Andrey Shaw, Chair
The podocyte forms the outer layer of the filtration barrier in the glomerulus to prevent albumin
leakage. Podocyte damage leads to focal segmental glomerulosclerosis (FSGS), a leading
cause of chronic kidney disease. The cause of the majority of FSGS cases is unknown and
referred to as sporadic FSGS. Genetic studies have identified genes as monogenic causes of
FSGS in patients with a strong family history, but these cases account for only a small proportion
of the FSGS population. Whether genetic susceptibility contributes to sporadic FSGS and which
cellular process in the podocyte initiates the pathogenesis of FSGS are important questions that
remain to be elucidated. To answer these questions, my research followed two different lines of
inquiry. I performed a genetic analysis of both familial and sporadic FSGS patients, and I
investigated the role of the actin cytoskeleton in podocytes. Based on expression analysis, we
identified a new FSGS susceptibility gene, ARHGAP24, and showed that it was mutated in a
family with FSGS. Since ARHGAP24 functions to maintain high Rho and low Rac levels, my
work suggested that this balance might be important in FSGS. Using an inducible transgenic
ix

mouse model and multi-photon intravital microscopy, we validated that high activity of Rac1, one
of the Rho family GTPases, is responsible for podocyte foot process effacement, increased
membrane dynamics, and podocyte shedding into the urine, three important processes that lead
to proteinuria and FSGS. By sequencing a large cohort of sporadic FSGS patients, I identified 16
potential FSGS susceptibility genes that were novel.

Using a novel podocyte-specific indicible

RNAi mouse model that I developed, four of these genes were validated. Some of these genes
function as regulators of the actin cytoskeleton. Our genetic study further reinforces the role of
actin cytoskeletal regulation in the pathogenesis of FSGS.

x

Chapter 1. Introduction

1.1 Podocytes form the outer layer of the kideny filtration barrier
The kidney is the organ where the urine forms. In adults, each kidney has 0.33~1.4 million
glomeruli [1]. The primary function of the glomerulus is to filter small solutes in the blood and to
generate the primary urine. During the filtration process, the blood flows into a tuft of capillaries
from the afferent arteriole. Molecules that are smaller than 40 kilodaltons (kD), including glucose,
urea, inorganic ions and water, pass through the filtration barrier, and enter the Bowman’s space
(Figure 1.1A). The filtration barrier is a three-layer structure: the inner layer is the fenestrated
endothelium; the middle layer is glomerular basement membrane (GBM), which is formed by
negative-charged and glycosylated extracellular matrix proteins; the outer layer is formed by a
kind of visceral epithelial cells, the podocycte (Figure 1.1B) [2].
Podocytes are unique-shaped epithelial cells that wrap around the glomerular capillaries.
They extend major (primary and secondary) processes from the cell body. The tertiary processes
(foot processes) interdigitate with those from neighboring podocytes to form a mesh-like network
(Figure 1.1B and 1.2A). The foot processes are connected by an electron-dense, ~40nm-wide
structure, the slit diaphragm, which composed of many adhesion proteins such as nephrin,
NEPH1, P-cadherin, and FAT (Figure 1.2B). As terminal-differentiated cells, podocytes rarely
proliferate post developmental period.
Pathological changes usually cause foot processes and the slit diaphragm to disappear.
1

The interface between two neighboring podocytes is flattened (Figure 1.3). This morphological
abnormality is usually referred to as “foot process effacement”. The loss of the organized foot
process–slit diaphragm meshwork is accompanied by the loss of the barrier function, and thus
large size proteins in plasma could leak into the Bowman’s space, which further results in
proteinuria. Albumin (MW ~70kD) leakage is measured as an indicator for the barrier function.

1.2 Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis (FSGS) is a glomerular disease that causes end stage
renal disease. As one of the leading causes, FSGS accounts for about 4% of the patients who
developed ESRD, and 40% of adult patients with nephrotic syndrome [3]. About ninety years ago,
Theodor Fahr, a German pathologist, published the first drawing of FSGS glomerulus with great
details [4]. Later, in 1957, A. Rich described that the cardinal characteristic of FSGS is
progressive scaring in some glomeruli [5]. In the early stage of this disease, sclerotic tissue (scar)
is found in a portion of the glomerulus (segmental), which only occurs in a subset of glomeruli
(focal) (Figure 1.4). The scarred glomerulus often exhibits other pathological features such as
mesangial hypercellularity and accumulation of foam cells in the capillaries [6]. Global sclerosis
can be diagnosed as FSGS progresses [7]. Recent studies suggest that the incidence of FSGS
has been increasing since the first clinical-pathological study in 1970s [3]. The major cell type
that is affected in this disease is the podocyte. At electron microscopic level, the cardinal feature
of FSGS is the effacement of podocyte foot processes. FSGS can be classified into familial
FSGS and sporadic FSGS base on the patient family history of this disease. Sporadic FSGS is
2

more common in the patient population.
Although the details of the pathogenesis of FSGS are not fully uncovered, genetic studies of
familial FSGS and animal models show that both genetic and environmental factors are
important in this disease. Genetic approaches have identified 8 genes, which are all specifically
expressed in the podocytes, as FSGS susceptibility genes: ACTN4 [8], ANLN [9], CD2AP [10–
12], INF2 [13], MYH9 [14, 15], NPHS2 [16], and TRPC6 [17, 18]. In African Amercian population,
APOL1-G1

and

-G2

alleles

cause

susceptibility

to

HIV-associated

FSGS

and

hypertension-associated kidney disease [19, 20]. The combined heterozygosity of Cd2ap and
Synpo induces FSGS in mice with incomplete penetrance: in 25% of the mice after 6 months of
age [21]. This result suggests that genetic background could contribute to the susceptibility to
FSGS. A nephrotoxic drug-induced FSGS model also supports this hypothesis. Adriamycin
induces severe glomerular injury and FSGS in BALB/cJ, 129X1/SvJ and 129SvImJ mouse
strains, but C57BL/6J strain is relatively resistant to this drug [22]. Recently Papeta et al
discovered the genetic cause of this phenomenon, C6418T SNP in Prkdc gene, by meiotic
mapping and genome sequencing [23]. This variant protects podocyte from mitochondria DNA
depletion during Adriamycin treatment. Thus, there could be other triggers, like drug treatment or
virus infection, which initiate the pathogenesis of FSGS.
Aging is also an important factor that contributes to the susceptibility of FSGS. Since
podocytes are terminal differentiated and they do not undergo mitosis to generate new
podocytes, the capacity of healthy podocytes to cover extra space is limited [24]. Each day,
hundreds of podocytes are shed into the urine, and capillary surface left will be covered by the
3

remaining healthy podocytes through a process called podocyte hypertrophy [25]. Diseases and
environmental factors that dramatically reduce podocyte number will be an important aspect of
FSGS pathogenesis, because when the capillary surface exceeds the capacity of the remaining
podocytes, the barrier system is permanently damaged and the damaged glomerulus will under
go sclerosis. Studies that use diphtheria toxin induced podocyte depletion in transgenic rats
show that >40% of podocyte depletion induces segmental to global glomerulosclerosis [26].

1.3 The actin cytoskeleton supports the morphology and function of
podocytes
Actin cytoskeleton is a dynamic cytoskeleton network in all eukaryotic cells. The
polymerization and depolymerization of actin filament networks allow the cell to form dynamic
structures that facilitate migration, cytokinesis, endocytosis, and other biological processes that
are essential to maintain the normal functions of a cell. Actin filaments can also form stable
bundles, which are named stress fibers, to facilitate the adhesion between cells and the extra
cellular matrix. Actin network is responsible for generating and transmitting force. Transverse
arches and dorsal stress fibers are the structures that are involved in generating force on the cell
body and transmit them to stress fibers and branched actin networks [27].
The fine structure of podocyte foot processes is supported by actin cytoskeleton network
[28]. Transmission Electron Microscopy (TEM) shows that there electron dense actin bundles are
enriched in the center of the foot processes, which are surrounded by loose cortical actin
networks (Figure 1.5A,B). These actin bundles initiate from the major processes. Curved actin
4

bundles connect the straight bundles of two neighbor foot processes that initiate from the same
major process [29] (Figure 1.5C). Details about how these structures form during podocyte
differentiation are still not known. The actin cytoskeleton network in the foot processes connects
the adhesive complex in the slit diaphragm, the focal contacts near the basement membrane,
and the apical cell membrane of the foot processes.
Slit diaphragm is an adhesive complex that maintains interaction between adjacent
podocytes. It connects to the actin cytoskeleton network inside the foot processes [30] (Figure
1.2B). Nephrin and Neph1 are transmembrane proteins that form the “zipper” like structure in the
slit diaphragm. They have large extracellular domains that bind to another Nephrin or Neph1
molecules from the adjacent podocyte. Nephrin has a small intracellular domain that binds to
several other cytoplasmic proteins like CD2AP and Nck [31–33]. Cd2ap directly bind to actin
filaments, cortactin, and capping proteins [34–37]. Nck recruit WASp, another nucleation factor
of actin filaments [38]. These proteins regulate branched actin network, and are believed to form
a signal hub that maintains the normal morphology of foot processes.
Other actin-associated proteins also play important roles in podocytes. Alpha-actinin4
(encoded by ACTN4) connects between actin fibers to form stable bundles [39]. INF2 (Inverted
formin 2) antagonizes the Rho-activated formin mediated actin polymerization and also the
localization of formin in cultured podoytes [40]. Non-muscle myosin IIA is responsible for tension
generation in response to the upstream signling on the actin bundles, and regulates podocyte
adhesion and migration [41]. Synaptopodin also functions to facilitate the polymerization of
G-actin [42]. It rescues the tropomyosin defects in drosophila and human cells [43].
5

The focal complexes that mediate the podocyte-GBM interaction also connect to actin
network in the foot processes. Focal complexes transmit the force that is generated by the
cytoskeleton networks inside the cell to the extracellular matrix. They also can sense the force
change outside the cell and convert it into intracellular signals. Integrin complexes are the
transmembrane proteins mediating the inside-out and outside-in signals [44]. In podocytes, the
most common integrin isoforms are α3β1 and αvβ3 [45, 46]. The extracellular domain of α3β1
and αvβ3 recognize laminin and collagen. The intracellular domains of multiple integrin
heterodimers assemble the platform of the focal complexes. Focal adhesion molecules, including
talin, zxyin, paxilin and vinculin form layers and connect to actin stress fibers. Kinases such as
FAK, SRC and ILK are regulated by the focal complex proteins and regulate the actin
cytoskeleton structure in vivo [47].

1.4 Rho Family GTPases are the main regulators of Actin cytoskeleton
Rho family guanosine triphosphatases (hereafter called Rho GTPases) are a family of
molecular switches that mainly regulate actin cytoskeleton structures [48]. The most studied
members are Rac1, RhoA and Cdc42. Rho GTPases cycles between GTP-bound, active
conformation and GDP-bound, inactive conformation. GTP-bound Rho GTPases activate the
downstream pathway by interacting with their effector molecules (Figure 1.6A). The C-terminus
of most Rho GTPases is modified by farnesyl or geranylgeranyl isoprenoid lipid, which is
required for membrane targeting. Active Rac1 recruits WAVE complex to the plasma membrane
and induces actin polymerization into branched network. Cells with high Rac activity forms large
6

lamellipodia (Figure 1.6B,C). GTP-bound RhoA, on the other hand, activates formin mediated
actin polymerization, resulting in long linear actin fibers and bundles (Figure 1.6B,C). Active
RhoA induces the assembly of stress fibers. Active Cdc42 induces finger-like extensions through
recruiting Wiskott–Aldrich Syndrome protein (WASp) to the plasma membrane and release its
auto-inhibitory conformation (Figure 1.6B,C). WASp further recruits Arp2/3 complex and
assembles thin, linear actin filaments, which protrude from the plasma membrane, and form
finger-like structures.
Direct modulation of the activity of Rho GTPases affects podocyte morphology and function
[49–51]. Podocyte-specific expression of CA-RhoA induced late onset of proteinuria and FSGS
[49]. Podocyte specific deletion of Cdc42 in mice causes congenital nephrotic syndrome and foot
process effacement [50]. However, deletion of either Rac1 or RhoA in podocytes does not induce
any defects in mice. Podocyte specific deletion of Rac1 in mice causes resistance to protamine
sulfate perfusion-mediated transient podocyte damage and foot process effacement, but
susceptibility to a chronic model of podocyte injury in UNX/DOCA-salt-hypertensive mouse
model [52].

1.5 Regulators of Rho GTPases
Three families of regulators mainly control the activity of Rho GTPases. Two classes of Rho
GTPase regulators control the processes of cycling between GTP- and GDP-bound states:
Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) (Figure
1.6A) [53]. The Rho GTPases are slow GTPases by themselves. The exchange between
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GDP-bound and GTP-bound forms is also ineffective. GEFs facilitate GTP loading, and increase
the level of active Rho GTPases. GAPs enhance the catalytic activity of Rho GTPases,
converting the active Rho family GTPases to the inactive state. A third family of regulatory
proteins are the guanine nucleotide dissociation inhibitors (RhoGDIs) (Figure 1.6A), which
sequester Rho GTPases at GDP-bound state, and pull it out of the cycling pool. RhoGDIs are
shown as “chaperones” for small GTPases because they stabilize GDP-bound state, and also
mediate the translocation of Rho GTPases between different membrane compartments [54, 55].
Although the exact physiological function of the Rho GTPase regulators has not been
extensively studied in podocytes, several studies indicate their crucial roles in regulating
podocyte morphology and function. RhoGDI-alpha knockout mice (Arhgdia-/-) exhibit congenital
nephrotic syndrome, and the knockout mice have high Rac activity in the kidney [56]. Tyrosine
phosphorylation on nephrin endoplasmic tail could also regulate p190RhoGAP through Rac [57].
Human protein atlas project has also identified GAPs and GEFs that are highly expressed in
podocytes, including ARHGAP12, ARHGAP28, ARHGAP35, SRGAP2, ARHGEF11, and
ARHGEF12 [58].
Some podocyte specific and/or FSGS susceptibility genes also regulate the activity of Rho
GTPases. Nephrin controls the Rac activity through PI3K-p85 signaling pathway [57].
Synaptopodin,

another

podocyte-specific

protein,

protects

Rho

from

degradation

by

Smurf-mediated ubiquitination, and inhibit the Cdc42-IRSp53 interaction [59, 60]. Mutations in
TRPC6, encoding a calcium channel, are associated with familial FSGS [17, 18]. Recently
studies showed that TRPC6 forms complex with RhoA, and TRPC5 forms complex with Rac1
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[61]. Calcium influx through TRPC6 increases active RhoA, while through TRPC5 increases
active Rac1. PLCE1, a risk gene for steroid resistant nephrotic syndrome and FSGS, is
responsible for efficient activation of Rac1 [62].

1.6 Large-scale genetic studies discover FSGS susceptibility genes
Next-generation sequencing (NGS) technologies, revolutionary sequencing methods
developed in early 2000s, allow researchers to access to personal genome in a faster and more
economic than traditional sanger sequencing method [63]. These methods read millions of
sequencing reactions simultaneously by high throughput monitoring approaches [64]. Using
NGS methods, researchers can identify specific genetic variants in a large cohort of patients.
These methods have been applied to investigate cancer genomes [65], to identify susceptibility
variants that associate with diseases such as autism and diabetes [66, 67], and to map the
epigenetic modification loci in the genome. Since the cost of whole genome sequencing for each
patient is still high, Hildebrandt’s group combines linkage analysis of familial nephrotic syndrome
with NGS recently identified several new genes that could cause FSGS, including ADCK4 [68],
ARHGDIA [69], and EMP2 [70].
Genome-wide association studies (GWAS) have been widely used to identify the linkage
between common variants that associate with diseases before NGS technologies became
popular. This method scan hundreds of thousands common DNA variant in human. Several
GWAS have identified 24 susceptible loci for chronic kidney disease, including SHROOM3,
UMOD, and DACH1 [71, 72]. GWAS method was also applied to study HIV-associated FSGS in
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African American population, and identified genetic locus between APOL1 and MYH9 that are
strongly associated with HIV-associated FSGS [14]. G1 and G2 variants of APOL1 are the
coding variants for FSGS susceptibility [19, 20].

1.7 Current mouse genetic models of podocyte diseases
Using in vitro models such as podocyte cell culture to study the function of podocytes is
limited since cultured podocytes do not generate foot processes. Thus in vivo models are
necessary to investigate and truly understand podocyte functions. Currently, transgenic and
knockout mouse models are the most widely used in vivo models for podocyte diseases. Rat
models are also commonly used and they are more susceptible to kidney damage than mouse
models. However, rats require more space and longer breeding period, and also the
transgenic/knockout tools in rat models are not as efficient as in mouse models. Knockout mouse
models have shown that many podocyte-specific genes and FSGS disease genes are essential
for maintaining the podocyte foot process structure in vivo, including Nphs1 [73], Nphs2 [74],
Neph1 [75], Actn4 [76], and Cd2ap [77]. Loss of function of some other genes in mice does not
cause any podocyte dysfunction, but increases the susceptibility to artificial kidney injury models,
such as Synpo [21], Trpc6 [78], and Myh9 [79]. The combinations of heterozygosity in
Cd2ap/Synpo and Cd2ap/Fyn also induce proteinuria and podocyte foot process effacement, the
early signs of FSGS in aged mice, indicating there could be genetic complexity in FSGS patients
[21].
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1.8 Intravital imaging by multi-photon microscopy
Since podocyte cell culture cannot recapitulate the foot process architecture in petri dishes,
intravital imaging is the only option to investigate the podocyte cell dynamics at the physiological
conditions. Currently multi-photon microscopy (MPM) is the best method to perform non-invasive
live imaging in vivo. This method based on a theory that multiple low-energy, long wavelength
photons can excite a fluorophore simultaneously (Figure 1.7A). The interaction between multiple
photons and the fluorophore will induce sequential electronic transition that equals to a single
high-energy photon [80]. The first MPM microscope was invented by Denk et al in 1990 [81].
Since low-energy, long-wave length photon is the source of excitation, MPM achieves three
following advantages: first, it penetrates tissue up to several hundred micrometers, which is
much deeper than another microscopy system; second, it reduces phototoxicity and bleaching of
the fluorophores; third, it reduces out-of-focus background signal because fluorophores are
excited only at the laser beam focus (Figure 1.7B) [82, 83]. Since the excitation is not linear,
second harmonic signal can be generated to visualize membrane structures like kidney capsule
and fascia by visualize their native fluorescence [84].
All the features make MPM an excellent approach to track podocytes in vivo. Using MPM,
Hackl et al showed podocyte migration in response to kidney injuries in podocin-GFP and
podocin-CRE confetti mice [85]. Endlich et al observed podocyte migration during the
development of zebrafish glomeruli. They also observed that zebra fish podocytes and their
11

branch patterns are stationary at physiological conditions [86]. Peti-Peterdi’s group also reported
increased calcium waves in podocyte during unilateral ureteral obstruction induced kidney injury
by using podocyte specific GCaMP mice [87].

1.9 Conclusions
The cell body of podocytes and the slit diaphragm between the interdigitating foot processes
from adjacent podocytes form the outer layer of the filtration barrier to prevent albumin leakage
into the primary urine. The organized structures of foot process and the slit diaphragm are the
indicators of the intact barrier function. In podocyte diseases, the effacement of foot processes
and the loss of slit diaphragm are often observed. These pathological changes are also
correlated with albuminuria. Actin network is the major cytoskeleton structure inside the foot
processes. Cortical Actin network connects the cell-cell adhesion of adjacent podocytes (slit
diaphragm) to the actin bundles in the center of the foot processes, which is thought to be the
cytoskeletal support of the foot process. Actin bundles are also connected to the focal complexes
that mediate the interaction between the podocytes and GBM. As the major regulators of actin
cytoskeleton, Rho family small GTPases are very important in maintaining foot processes and
slit diaphragm. Previous studies have indicated that dysregulation of the activities of Rho
GTPases could cause foot process effacement and glomerulosclerosis. However, it is not fully
understood about which small GTPase play the most important role in the podocyte damage.
FSGS, a leading cause of end stage renal failure, is one of the diseases that caused by
podocyte damage. It remains unknown about how much genetic risk causes susceptibility to
12

FSGS. FSGS can be classified as familial FSGS and sporadic FSGS based on whether another
family member is diagnosed with the same disease or not. Genetic studies of familial FSGS
cases have identified many FSGS causing genes, most of which are components of the slit
diaphragm, and/or regulate the actin cytoskeleton structure. Gain or loss of function mutations of
FSGS genes could cause actin cytoskeleton remodeling in the podocytes, which could be the
reason of foot process effacement. However, FSGS genes do not explain the sporadic form of
this disease, because they are rarely mutated in sporadic cases. Whether there is a genetic
factor and how much of the genetic risk is in the sporadic FSGS remain to be investigated.
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1.10 Figures

Figure 1.1 The structure of the glomerulus
(A) The image showed the composition of the glomerulus. Afferent arteriole branched into
capillaries ball inside the Bowman’s capsule. During the filtration process, water and small
solutes can penetrate through the filtration barrier and become the glomerular ultrafiltrate. The
rest of the blood including blood cells and proteins remain in the capillary loops, which combine
to form the efferent arteriole. (B) The structure of the filration barrier. The capillaries inside the
Bowman’s capsule are fenestrated. They are covered by podocytes. Between foot processes of
the podocyte, big transmembrane proteins form an adhesive structure called slit diaphragm
(filtration
slits).
(Adjusted
from
Human
Physiology,
Chapter
12,
https://humanphysiology2011.wikispaces.com/12.+Urology, by Rausch A and Kortleever C)
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Figure 1.2 The podocyte and the slit diaphragm
(A) Scanning microscopy of the podocyte. FP: foot processes; P: primary processes. (B) A
cartoon of the cross-section view of foot processes and slit diaphragm. Important proteins and
their locations are also shown [88, 89].

Figure 1.3 Foot process effacement
(A) A cartoon showed the effaced podocytes loose their foot processes. The effaced area looks
like lamellipodia. (B) Transmission electron microscopy shows normal and effaced foot
processes.
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Figure 1.4 Histology of FSGS
The upper glomerulus shows features of glomerulosclerosis on the left lobe. The lower
glomerulus is normal. The red-staining area on the left lobe of the upper glomerulus shows sign
of scarring (scleosis). (A mouse kidney was stained by a method called periodic acid-Schiff stain)

Figure 1.5 The actin cytoskeleton in the podocyte foot processes
(A) An cross-section image of a foot process imaged by transmission electron microscopy. The
arrow showed the actin bundle in the center of the foot processes, the star showed the loose
actin network at the bottom of the foot processes and surrounding the actin bundle. The
arrowheads show the slit diaphragm. (B) A cartoon of a foot process. AB: Actin bundles, CAN:
cortical actin network, SD: slit diaphragm, GBM: glomerular basement membrane, and En:
endothelial cells. (C) A bird view image of foot processes. The open arrow shows curved actin
bundles that connects adjacent foot processes extended from the same podocyte; the closed
arrows show the straight actin bundles inside the foot processes. This figure is adapted from
Sakai et al [29].
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Figure 1.6 Rho Family GTPases: regulation and function
(A) The regulated catalytic cycle of Rho family GTpases. Lipid modification allows Rho GTPases
attach to the membrane structures in the cell. GEFs facilitate the exchange of GDP to GTP and
convert GDP-bound Rho GTPases to GTP-bound form. GTP-bound Rho GTPases activate the
downstream effectors through allosteric mechanisms. GAPs stimulate the GTPase activity of
Rho family GTPases and convert the GDP-bound form to GDP bound form. RhoGDI proteins
bind the GDP-bound form, and pull it our from the membrane structure. (B, C) Active Rho
stimulates stress fiber formation through mDia, activate Rac stimulates lamellipodia formation
through WAVE complexes, and active Cdc42 stimulates filopodia formation through WASP. This
figure
is
adapted
from
Tubulewicz
et
al
[90]
and
http://www.mechanobio.info/modules/go-0051893
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Figure 1.7 The mechanism and advantage of multi-photon microscopy (MPM)
MPM reduces the fluorescent background compare to single photon microscopy. This figure is
adapted from
http://cleoqels2010.blogspot.com/2010/05/expo-idea-generation-and-multiphoton.html
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Chapter 2. Arhgap24 Inactivates Rac1 In mouse Podocytes, and A mutant Form is
Associated with Familial Focal Segmental Glomerulosclerosis

2.1 Abstract
Podocyte has a complex actin-based cytoskeleton that maintains efficient barrier function of
glomeruli. Disruption of components of the actin cytoskeleton results in podocyte damage and
cell loss, which may lead to a prototypic injury response called focal segmental
glomerulosclerosis (FSGS). From genes that are highly expressed in mouse podocytes, we
identified a RhoA-activated Rac1 GTPase-activating protein, Arhgap24, which was upregulated
in podocytes as they differentiated, both in vitro and in vivo. Decreased Arhgap24 expression
results in high level of active Rac1 and Cdc42, which influenced the cell shape and membrane
dynamics. Consistent with a role for Arhgap24 in maintaining normal podocyte functions in vivo,
we identified a mutation in Arhgap24 that impaired its Rac1-GAP activity by sequencing FSGS
patients and that was associated with disease in a family. Thus, Arhgap24 contributes to the
careful balancing of RhoA and Rac1 signaling in podocytes, the disruption of which may lead to
kidney disease.

2.2 Introduction
The kidney filters plasma and reabsorb salts and nutrients to maintain the appropriate
extracellular environment. The proximal component of the nephron, the glomerulus, is the
primary filtration barrier that prevents the loss of serum proteins into the primary filtrate. The
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glomerular filtration barrier consists of fenestrated endothelial cells, a thick glomerular basement
membrane (GBM), and specialized epithelial cells (podocytes) arranged in series. Diseases
affecting the filtration barrier, especially of the GBM or the podocyte, result in the leakage of
serum proteins into the urine, progressive damage to the glomerulus, and loss in renal function
[91].
The podocyte has a complex cellular architecture composed of an octopus-like cell body
that attaches to the GBM through actin-based foot processes [88]. In kidney diseases that are
associated with proteinuria, such as focal segmental glomerulosclerosis (FSGS) and minimal
change disease, podocytes rearrange their actin cytoskeleton network, which results in retraction
or effacement of foot processes [92]. While it is unclear how this change leads to the leakage of
serum proteins, foot process effacement appears to be a key step in the breakdown of the
filtration barrier. Studies to understand the molecular basis of foot process effacement in vitro
have shown that, in response to stress, podocytes switch from a RhoA-dependent stationary
state to a Cdc42- and Rac1-dependent migratory state [28, 93]. These studies suggest the
intriguing possibility that altered membrane dynamics and increased cell motility are the
mechanisms underlying foot process effacement in vivo.
Since podocyte membrane reorganization is a common feature of proteinuric kidney
diseases, we sought to understand the regulation of membrane dynamics of these cells. Using
an in vitro model of podocyte differentiation, we found that podocytes reduced their membrane
ruffling activity as they were differentiated. We found that decreased membrane ruffling in
differentiated podocytes was dependent on the presence of a GTPase-activating protein (GAP),
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Arhgap24. Previous works from Stossel and colleagues have shown that Arhgap24 (also known
as Filamin A-binding RhoGAP [FilGAP]) is a GAP for Rac1, and it binds to branched actin
network and suppresses lamellipodia formation and cell spreading downstream of RhoA
signaling [94]. Their work also shows that the highest level of Arhgap24 transcript is in the kidney.
Here we show that Arhgap24 was specifically expressed in podocytes in the kidney. Its
expression increased as these cells differentiate in vivo. The ARHGAP24 gene is highly
conserved, implying an important role for the gene product. We sequenced the DNA from
patients with FSGS, and identified a loss-of-function mutation in the ARHGAP24 gene in kindred
with familial kidney disease. Taken together, these results suggest that Arhgap24 controls the
RhoA-Rac1 signaling balance in podocytes that could be dysregulated in proteinuric kidney
diseases, such as FSGS.

2.3 Methods
2.3.1 Podocyte cell culture
Generation and propagation of conditionally immortalized murine podocyte cell lines has
been described previously [95, 96]. Briefly, podocytes were propagated on collagen I–coated
dishes at 33°C (permissive temperature) in RPMI supplemented with 10% fetal bovine serum
(FBS) and 10 U/ml of recombinant mouse interferon-γ (IFN-γ, a gift from Robert Schreiber,
Washington University School of Medicine). To induce differentiation, the medium was changed
to RPMI with 5% FBS without IFN-γ, and the cells were shifted to 37°C (nonpermissive
temperature) for 7 to 14 days. Under these conditions, cells underwent growth arrest, increased
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in size, and developed elongated cell processes.
For live cell imaging experiments, podocytes were stably transduced with YFP-actin by
lentivirus transduction, and purified by automated cell sorting. Control and knockdown cell lines
were generated using a bicistronic lentiviral vector incorporating the targeting shRNA and
YFP-actin expressed downstream of an internal ribosomal entry site. The control knockdown
sequence targeted the firefly luciferase gene (Fluc). The 2 Arghap24 knockdown constructs
targeted

the

sequences

5′-TTAAGGAGCTAATGAAACA-3′

(line

451)

and

5′-TAACGATGGTCATAAGAAA-3′ (line 756), respectively. Stably transduced cell lines were
generated by automated cell sorting for YFP expression.
2.3.2 RNA isolation
Isolation of primary mouse podocytes using Dynabead perfusion and flow cytometric cell
sorting has been described previously [97, 98]. RNA was extracted from 6,000 primary
podocytes and from cultured podocytes grown at the permissive or nonpermissive temperatures
using an RNeasy Kit (Qiagen) following the manufacturer’s protocol. RNA quality was verified by
gel electrophoresis and to ensure that the 260/280 nm absorbance ratio was greater than 1.8.
2.3.3 Arhgap24 antiserum production
Amino acids 390–604 of isoform 1 (NCBI accession no. NP_083546) of mouse Arhgap24
were cloned downstream of glutathione-S-transferase (GST) in the pGEX4T-1 expression vector.
This portion of Arhgap24 is well conserved across species and lies downstream of the GAP
domain in both isoforms of Arhgap24. GST-tagged Arhgap24 was expressed in BL21 (DE3)
pLysS E. coli. After induction with IPTG and sonication of bacteria, soluble GST-Arhgap24 was
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batch purified using glutathione-agarose beads. GST-Arhgap24 was eluted with reduced
glutathione and dialyzed against PBS to remove excess glutathione. This antigen was emulsified
in complete Freund’s adjuvant (Sigma-Aldrich) and was used to immunize rabbits and Armenian
hamsters. Hamster handling and immunization were performed by the Washington University
School of Medicine Hybridoma Center. Specificity for Arhgap24 was confirmed by
immunoblotting FLAG-tagged Arhgap24 transfected into HEK293 cells. Specific signal in
immunoblotting and staining experiments was confirmed by quenching of signal with antiserum
preincubated with antigen.
2.3.4 Confocal imaging
Podocytes grown on sterilized collagen I–coated coverslips at 33°C or 37°C were fixed with
4% PFA in PBS for 10 minutes. Cells were then blocked and permeabilized for 1 hour with PBS
with 2.5% FBS and 0.1% saponin. Primary rabbit anti-Arhgap24 antiserum (1:300) in blocking
buffer was applied to the cells for 1 hour at room temperature. After four 5-minute washes with
blocking buffer, coverslips were mounted using ProLong Antifade mounting medium (Invitrogen)
according to the manufacturer’s protocol. Images were captured with confocal settings using an
Olympus FluoView FV1000 microscope. A similar protocol was used to stain Arhgap24 in
formalin-fixed paraffin-embedded mouse kidney after antigen retrieval. Podocytes were stained
using a mouse anti-synaptopodin monoclonal antibody (a gift from Peter Mundel, Massachusetts
General Hospital, Boston, Massachusetts, USA) [99]. For wound healing experiments,
differentiated knockdown podocytes were plated to confluence on collagen I–coated coverslips.
A scratch was created using a sterile 200 µl pipette tip. Loosely adherent cells were washed
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away by 3 vigorous washes with PBS. The cells were transferred to culture medium, and, at
various time points, coverslips were harvested and fixed in 4% PFA in PBS. Cells were identified
by nuclear staining with DAPI (4',6-diamidino-2-phenylindole).
2.3.5 Tissue isolation and immunoblotting
Whole mouse tissues (~200 mg) were snap frozen on dry ice and homogenized in cold
lysis buffer containing 1% NP-40 and protease inhibitors using a dounce homogenizer. Post
nuclear supernatants were loaded to equalize actin levels by immunoblotting. Glomerular
isolation/enrichment experiments using magnetic particles were performed as described
previously [97].
2.3.6 Live cell imaging and kymograph analysis
Podocytes that were lentivirally transduced with YFP-actin were cultured in glass bottom
dishes at 33°C or differentiated at 37°C (nonpermissive condition) for 7 to 14 days and then
imaged. Similarly, YFP-actin transduced Arhgap24 knockdown (lines 451 and 756) and control
knockdown (Fluc) cell lines were differentiated on glass bottom dishes for 7 to 14 days before
imaging experiments. Sequential images were captured every 15 seconds for a 20-minute
duration using an Olympus FluoView FV1000 microscope. Movies were assembled using
Olympus Fluoview software. The Multiple Kymograph plug-in of ImageJ ( http://rsbweb.nih.gov/ij/)
was used to generate kymographs at 3 different locations of maximal membrane ruffling for each
cell imaged [100]. For each kymograph, up to 13 actin spikes were measured, and the average
length was computed as described previously [101]. A value of 1 was assigned to kymographs
without a measurable actin spike. Ruffling movies were generated by H. Suleiman, and the
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kymographic analysis was performed in a blinded fashion by S. Akilesh. Images were assembled
in Adobe Photoshop.
2.3.7 Sequencing
DNA was obtained from affected (n = 310) and control (n = 180) individuals. DNA from 96
of the control individuals was purchased from the Coriell Institute. PCR primer pairs were
designed to completely sequence exons and exon-intron junctions of ARHGAP24. Bidirectional
sequencing using ABI Big Dye 3.1 sequencing chemistry on an ABI PRISM 3730 sequencing
platform (Applied Biosystems) was performed. Sequences were aligned using Sequencher
software (Gene Codes) and manually verified. The Q158R variation was determined by A.S.
Shaw’s laboratory and verified by M.P. Winn’s laboratory. In addition, the exon incorporating this
variation was sequenced in an additional 554 control chromosomes to rule out the possibility that
it represented a low-frequency noncausal variation.
2.3.8 Haplotype analysis
MSM primer sequences for markers D4S1538, D4S1534, D4S2409, and D4S2460 were
obtained from UniSTS (http://www.ncbi.nlm.nih.gov/unists) or designed with Primer3 software
(http://frodo.wi.mit.edu/primer3/). Carboxyfluorescein succinimidyl ester–labeled (FAM-labeled)
oligonucleotides were synthesized by Invitrogen Life Technologies and were run on the 3730
DNA Analyzer (Applied Biosystems) and analyzed using GeneMapper Software v4.0 (Applied
Biosystems). The analysis was carried out by visual inspection, assigning the most likely linkage
phase by minimizing the number of recombinants in the pedigree.
2.3.9 Arhgap24 dimerization assay
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FLAG- or GFP-tagged wild type or Q156R Arhgap24 were cotransfected into HEK293 cells.
Cell lysates were immunoprecipitated with M2 mouse anti-FLAG antibody (Sigma-Aldrich) with
protein A conjugated to sepharose beads. The immunoprecipitates were resolved by SDS-PAGE
and then immunoblotted with JL-8 mouse anti-GFP antibody (Invitrogen).
2.3.10 Rac1, Cdc42, and RhoA pull-down assays
The GST-tagged Pak1-PBD used for the pull-down assays was expressed in BL21(DE3) E.
coli. The recombinant protein was bound to glutathione-agarose beads stored at –80°C until use.
For the active Rac1 pull-down assay, HEK293T cells were seeded in 6-cm dishes and
transfected at 80%–90% confluence using Lipofectamine 2000 reagent according to the
manufacturer’s protocol (GIBCO BRL). Cells were transfected with FLAG-tagged wild-type or
mutant Q156R Arhgap24 or a titration of the 2 constructs, keeping the total DNA transfected
constant. Twenty-four hours after transfection, the cells were lysed, and a sample of the lysate
was retained for measurement of total Rac1 and FLAG-Arhgap24 levels. Equal volumes of the
remaining lysates were incubated with GST-PBD bound to glutathione-agarose beads.
Rac1-GTP bound to the beads (active Rac1) was eluted with Laemmli sample buffer and
separated on a 12% polyacrylamide gel. After transfer to a nitrocellulose membrane, active and
total Rac1 were detected with the 23A8 mouse anti-Rac1 monoclonal antibody (Upstate
Biotechnology). FLAG-tagged Arhgap24 was detected with the M2 mouse anti-FLAG antibody.
For Cdc42 activity assays, active Cdc42 was immunoprecipitated with GST-PBD bound to
glutathione-agarose beads and detected with B-8 mouse anti-Cdc42 (Santa Cruz Biotechnology
Inc.). For RhoA activity assays, active RhoA was immunoprecipitated with GST-Rhotekin bound
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to glutathione-agarose beads and detected with 26C4 mouse anti-RhoA (Santa Cruz
Biotechnology Inc.). The immunoblot signal was detected using a LI-COR Odyssey Imaging
System using their infrared dye-labeled secondary reagents. Data are representative of at least 3
independent experiments.
2.3.11 Statistics
Data are represented as mean ± SD. In all cases, group differences were assessed by
ANOVA with post-test correction (Bonferroni-Holm). A P value of less than 0.05 was considered
significant.
2.3.12 Study approval
Patient and control DNA samples were obtained after written informed consent and with
local Institutional Review Board approval (Washington University School of Medicine, Duke
University Medical Center, Université René Descartes, Brigham and Women’s Hospital, and the
NIDDK). All animal experiments were conducted with approval of the Washington University
Animal Care and Use Committee

2.4 Results
2.4.1 Differentiated podocytes reduce ruffling of their cell membranes
Podocytes can be propagated in vitro by conditional expression of a temperature-sensitive
SV40 large T antigen at the permissive temperature of 33°C. Shifting the cells to the
nonpermissive temperature (37°C) induces destabilization of the large T antigen, growth arrest,
and morphologic changes that mimic podocyte differentiation in vivo [95]. During development,
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podocytes reorganize their cell membranes from broad sheets into sieve-like foot processes [88].
Conversely, in proteinuric diseases, podocytes lose this membrane complexity and exhibit
effacement of their foot processes [92]. Therefore, we hypothesized that the membrane
dynamics of podocytes would be regulated in this in vitro model of cell differentiation. When
undifferentiated podocytes were cultured at the permissive temperature, they exhibited highly
ruffled plasma membranes (Figure 2.1A). In contrast, the plasma membranes of the
differentiated podocytes had a very smooth, flat appearance. In order to quantitate these
membrane dynamics, we performed time-lapse imaging of live podocytes transduced with yellow
fluorescent protein–actin (YFP-actin). While undifferentiated podocytes rapidly ruffled their
membranes, differentiated podocytes had reduced membrane motility, correlating with the
reduced frequency of ruffled cell membranes (Supplemental Videos 1 and 2; supplemental
material available online with this article; doi: 10.1172/JCI46458DS1). This difference is also
apparent by kymographic analysis (Figure 2.1A and 2.1B).
2.4.2 Podocytes upregulate Arhgap24 when they differentiate
Next, we evaluated the expression of the small G proteins and their regulators that might
control membrane motility in this in vitro model of podocyte differentiation. We isolated RNA from
undifferentiated and differentiated mouse podocytes and performed gene expression analysis
using microarrays. Our cultured podocytes expressed genes for several known podocyte-specific
proteins, such as Wilms tumor protein 1 (Wt1), podocin (Nphs2), CD2-associated protein
(Cd2ap), podocalyxin (Podxl), synaptopodin (Synpo), α-actinin-4 (Actn4), and to a lower extent
nephrin (Nphs1). We focused our analysis on the expression patterns of known regulators of the
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actin cytoskeleton and membrane dynamics, such as GAPs and guanine nucleotide exchange
factors (GEFs) for Rac1, RhoA, and Cdc42 (a list of these genes is available as a supplemental
data

table

in

the

Gene

Expression

Omnibus

(GEO)

database,

series

GSE23856; http://www.ncbi.nlm.nih.gov/gds/). Of these known GAPs and GEFs, the message
for Arhgap24 was highly upregulated when podocytes were differentiated in vitro. Arhgap24 was
an intriguing gene, because previous work from Stossel and colleagues had shown high
transcript levels in the kidney [94]. However, the cell expressing Arhgap24 within the kidney was
unknown. We found that RNA from in vivo–isolated podocytes also had a high level
of Arhgap24 transcript [96]. Next, we examined Arhgap24 gene expression in publicly available
microarray data (the GenitoUrinary Molecular Anatomy Project; www.gudmap.org) generated
from microdissected glomeruli isolated at various stages of kidney development. The
Arhgap24 message was upregulated as glomeruli progressed from the E12.5 renal vesicle stage
to the E15.5 S-shaped body to the almost mature E15.5 renal corpuscle (Figure 2.2A).
We confirmed the microarray results by quantitative RT-PCR. Arhgap24transcript levels
increased ~70 fold when podocytes were differentiated (Figure 2.2B). To confirm upregulation at
the protein level, we generated Arhgap24-specific antiserum in Armenian hamsters and rabbits.
Preabsorption of these antisera with Arhgap24 antigen abolished specific signal (Supplemental
Figure 2.1). Podocytes upregulated a 95-kDa band corresponding to the Arhgap24 protein when
they were differentiated in vitro (Figure 2.2C). The lower band seen in the undifferentiated
podocytes (at approximately 50 kDa) did not correspond to the predicted molecular weight of
known splice isoforms of Arhgap24. This 50kDa bind likely represents a specific degradation
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product of Arhgap24, perhaps due to increased turnover of the protein in undifferentiated
podocytes. Confocal imaging of podocytes showed that Arhgap24 was enriched in structures at
the base of the cell, and the staining intensity at these sites increased with differentiation
(Figure 2.2D). Since Arhgap24 has been described to localize to focal adhesions [94], we
verified that these structures were in fact focal adhesions by co-labeling with vinculin
(Figure 2.2E). These experiments showed that Arhgap24 is highly expressed in the focal
adhesions of cultured podocytes and is upregulated as these cells are differentiated.
2.4.3 Arhgap24 is expressed in kidney podocytes in vivo
Next, we tested Arhgap24 expression and localization in murine tissues and its specific
localization within the kidney. Immunoblotting of lysates from several tissues showed that the
highest level of full-length Arhgap24 protein (95-kDa band) was in the kidney. Again, the
approximately 50-kDa putative breakdown product was seen in lysates from the brain, kidney,
and liver. We then evaluated whether Arhgap24 was expressed in the glomeruli of the kidney.
We trapped magnetic particles within the glomeruli by beating heart perfusion and then used
magnetic separation to isolate whole glomeruli to more than 95% purity (Figure 2.3B). Arhgap24
was enriched in the glomerular fraction (verified by podocin immunoblotting) compared with the
flow through fraction that contained mostly tubule fragments (Figure 2.3C). Next, we stained
sections of mouse kidney and detected the greatest signal within glomeruli (Figure 2.3D). This
signal was specific since it was completely abolished by preabsorption of the antiserum with
Arhgap24 antigen (Data not shown). Within the glomeruli, the Arhgap24 signal colocalized with
the podocyte marker synaptopodin, confirming that Arhgap24 is expressed in podocytes in vivo
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(Figure 2.3E).
2.4.4 Arhgap24 knockdown restores membrane ruffling in differentiated podocytes
Having established that Arhgap24 is expressed in podocytes in vitro and in vivo, we next
asked whether it was responsible for the dramatic decrease in membrane ruffling that we
observed in differentiated podocytes (Figure 2.1). Membrane ruffling is dependent on the activity
of the small G protein Rac1 [102]. Rac1 cycles between an active, GTP-bound state and an
inactive, GDP-bound state. When activated by GEFs, Rac1 interacts with multiple downstream
effectors to stimulate actin nucleation and branching required for lamellipodia formation and
membrane ruffling. Subsequently, Rac1 can be inactivated by GAPs that stimulate the intrinsic
GTPase activity of Rac1, resulting in the hydrolysis of GTP to GDP. Previous work has shown
that Arhgap24 is a GAP protein that inactivates Rac1 [94]. Since Arhgap24 is upregulated in
podocytes as they differentiate, it was a logical candidate to inactivate Rac1 and thereby slow
membrane ruffling in differentiated podocytes.
We investigated whether Arhgap24 upregulation was responsible for the reduced Rac1
activity and membrane motility of differentiated podocytes. We generated podocyte cell lines
(lines 451 and 756) with 2 different Arhgap24 lentiviral knockdown constructs that coexpressed
the YFP-actin reporter. Compared with that of the control vector (Fluc), the podocyte cell lines
transduced with the 2 knockdown constructs resulted in approximately 85% (line 451) or 60%
(line 756) downregulation of the Arhgap24 protein in differentiated podocytes (Figure 2.4A). After
differentiation, the control and 2 Arhgap24 knockdown cell lines were assayed for their
membrane motility as before. Compared with that of the control knockdown, Arhgap24
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knockdown resulted in increased membrane motility in differentiated podocytes (Figure 2.4B and
Supplemental Videos 3–5). Kymograph analysis showed that Arhgap24 knockdown significantly
increased membrane motility (Figure 2.4C).
Since Arhgap24 inhibits Rac1 and Cdc42 activity, we asked whether Arhgap24 knockdown
resulted in increased levels of active Rac1 and Cdc42 in differentiated podocytes. We measured
active Rac1, Cdc42, and RhoA by standard pull-down assays and found that the Arhgap24
knockdown cell lines had higher levels of active Rac1 and Cdc42 compared with those of the
control knockdown cell line (Figure 2.5A). Interestingly, Arhgap24 knockdown did not affect
RhoA activity. Another assay of Rac1 activity is epithelial monolayer wound closure. When a
confluent monolayer of differentiated control knockdown podocytes was scratched/wounded, the
cells migrated into the gap but did not completely close the wound in 24 hours. In contrast, both
Arhgap24 knockdown cell lines showed accelerated wound closure kinetics, consistent with
higher Rac1 activity (Figure 2.5B). Thus, Arhgap24 knockdown increases levels of active Rac1
and Cdc42. Two measures of increased Rac1 activity, membrane ruffling and epithelial wound
closure, are enhanced when Arhgap24 levels are reduced in podocytes, consistent with its
function as a Rac1-GAP.
2.4.5 Sequencing ARHGAP24 in patients with FSGS identifies several nonsynonymous changes
in a highly conserved gene
Given the podocyte-specific pattern of expression of Arhgap24 and its effects on
membrane dynamics and epithelial wound healing, we next asked whether variations
in ARHGAP24 were associated with kidney disease. The ARHGAP24 gene consists of at least 8
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exons (depending on the splice isoform) that span approximately 500 kilobases on the long arm
of human chromosome 4. Complete exon sequencing of the ARHGAP24 gene in 310 patients
(620 chromosomes) with biopsy-proven FSGS and 180 controls (360 chromosomes) identified
13 nonsynonymous sequence variations in the 2 main splice isoforms of Arhgap24 (Table 2.1).
Two of these (P417A and F539L) were found in both patients and controls and also in the 1000
genomes

database

(www.1000genomes.org)

(Table

2.2).

However,

seven

of

the

nonsynonymous changes were only found in patients and not in any of the controls. These
results suggest that variation in the ARHGAP24 gene may be linked with susceptibility to FSGS.
2.4.6 Identification of an ARHGAP24 variation in familial FSGS
Most of the nonsynonymous changes that we detected in patients with FSGS were in the
uncharacterized portions of the Arhgap24 protein. However, 1 of the sequence variations
(Q158R) is located in the GAP domain of Arhgap24 close to the catalytic arginine (residue 175).
This variation is predicted to result in a coding change that would substitute a positively charged
arginine for a neutral polar glutamine at position 158 (isoform 1; NCBI accession no.
NP_001020787) or position 65 (isoform 2; NCBI accession no. NP_112595). Remarkably, this
residue is conserved in the ARHGAP24 gene across several model organisms that have been
sequenced (Table 2.3). Of the other 2 nonsynonymous variations for which pedigree DNA was
available (T97I and P417A), neither variation reliably correlated with disease status (Figure 2.6).
We first identified the Q158R variation in a Hispanic proband and explored the association
of this variation with kidney disease in his family (Figure 2.7). The proband (patient number 1)
had elevated serum creatinine levels (16 mg/dl), and a biopsy that was performed at age 20 that
33

showed FSGS. His sister (patient number 101) also had biopsy-proven FSGS that had
progressed to end-stage kidney disease by age 12. The mother (patient number 1001)
presented at a late stage and died at age 29 of renal failure. Sequencing showed that the
patient’s affected sister and his mother both had the Q158R variation in theARHGAP24 gene. In
contrast, the proband’s 2 other siblings did not possess this variation. The brother (patient
number 100) remains healthy, but the sister (patient number 102) had pregnancy-related
proteinuria and hypertension. A biopsy was not performed on this individual, and she was lost to
follow-up. However, an extended haplotype consisting of 4 flanking microsatellite markers
(MSMs) showed that the haplotype of this sister was similar to that of the unaffected brother,
making a disease-contributing rearrangement in this region of the genome unlikely (Figure 2.7).
In addition, the exon incorporating this variation was sequenced in an additional 554
control chromosomes (for a total of 914 control chromosomes) to decrease the probability that it
represented a low-frequency noncausal variation. Altogether, we had sequenced over 900
control chromosomes across this span and did not detect the Q158R change. We also
sequenced members of the affected kindred for mutations in genes known to cause hereditary
FSGS and nephrotic syndrome, such as NPHS1, NPHS2, ACTN4, transient receptor potential
cation

channel, subfamily

C, member 6

(TRPC6), phospholipase

C, e1

(PLCE1),

and WT1 (exons 8 and 9) and inverted formin, FH2 and WH2 domain containing (INF2) (data not
shown). There were no suggestive mutations in any of these genes, ruling out known monogenic
causes of FSGS in this family. Therefore, in kindred with familial FSGS, the Q158R variation of
the ARHGAP24 gene tracked with severe, early-onset kidney disease.
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2.4.7 Arhgap24 Q158R has reduced Rac1-GAP activity
Another

possibility

was

that

a

cosegregating

mutation

closely

linked

to

the ARHGAP24 gene was responsible for early-onset kidney disease. We therefore tested
whether the Q158R variation produced a defective form of the Arhgap24 protein. The Q158R
variation is located close to the catalytically active site arginine residue of the GAP domain, and
so we evaluated whether this change affected the Rac1-GAP activity of Arhgap24. For these
experiments, we used the mouse Q156R protein, which corresponds to Q158R in human
Arhgap24. As expected, wild type Arhgap24 reduced the level of active Rac1 in cell lysates,
showing again that it has GAP activity against Rac1 (Figure 2.8A). In contrast, transfection of the
Q156R-mutated Arhgap24 resulted in a marked increase in the level of active Rac1. Titrating
increasing levels of Q156R Arhgap24 against the wild-type protein confirmed that the Q156R
mutation impairs the GAP activity of Arhgap24. Next, we tested whether the Q156R variant
Arhgap24 could homodimerize and/or heterodimerize with the wild-type protein. FLAG- and
GFP-tagged wild-type and Q156R versions of murine Arhgap24 were cotransfected into HEK293
cells. In bidirectional pull-down assays, we detected that both wild type and Q156R Arhgap24
homodimerized and heterodimerized (Figure 2.8B). These experiments showed that the Q158R
mutation reduces the enzymatic activity Arhgap24. The fact that Arhgap24 dimerizes may
explain the observed dominant effect of this mutation in our family with inherited kidney disease.

2.5 Discussions
Arhgap24, also known as FilGAP and p73RhoGAP, is the protein product of a highly
35

conserved gene encoded on human chromosome 4. The longer isoform of Arhgap24, which we
have used exclusively in this report, is highly expressed in the kidney [94]. GAPs such as
Arhgap24 and GEFs for small G proteins comprise a large family of proteins that have diverse
patterns of spatial and temporal expression [103]. Such a restricted pattern of expression may
allow GAPs and GEFs to behave as cell-type specific effectors for ubiquitously expressed actin
regulatory proteins. Here, we show that Arhgap24 is one such candidate for cytoskeletal
regulation of the kidney podocyte.
The small G proteins, Rac1, Cdc42, and RhoA, control cell shape and motility through their
effects on the actin cytoskeleton. In many systems, RhoA and Rac1 are mutually antagonistic
[104, 105]. However, the molecular basis of this counterregulation had been unclear until the
discovery of Arhgap24. Stossel and colleagues showed that, in response to RhoA activation,
Arhgap24 is phosphorylated by the RhoA effector kinase, ROCK, and this modification
stimulates its GAP activity for Rac1 and Cdc42 [94]. By catalyzing the conversion of Rac1 and
Cdc42 to their inactive GDP-bound state, Arhgap24 inhibits cell spreading and cell motility.
Recently, a similar mechanism was demonstrated for the closely related family member,
Arhgap22, in melanoma cells [106]. The diversity of GAPs likely ensures that specific ones may
play a role in Rac1-RhoA counterregulation in different cell types and tissues.
Recent work from several groups has shown that the balance of RhoA and Rac1 signaling
is carefully regulated in podocytes. Normally, the podocyte appears to be a stationary cell with
predominantly active RhoA signaling. The podocyte-enriched adaptor protein synaptopodin
controls a signaling module that promotes RhoA activity via 2 different mechanisms.
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Synaptopodin blocks Smurf1-mediated ubiquitination and subsequent proteasomal degradation
of RhoA [59]. Synaptopodin also disrupts IRSp53 binding to the Cdc42-Mena complex,
interrupting Cdc42 signaling that opposes RhoA-mediated stress fiber formation [60].
Synaptopodin itself is phosphorylated and protected from degradation by binding to 14-3-3 [107].
Conversely, when it is dephosphorylated by calcineurin, synaptopodin is degraded by cathepsin
L [107]. The net result is that reduced synaptopodin levels lead to decreased RhoA levels and
activity [59].
The RhoA-Rac1 signaling balance in podocytes is also responsive to hormonal stimulation.
Binding of the vasoactive hormone angiotensin II to its receptor, angiotensin receptor type I
(AT1R), leads to a calcium flux through the channels Trpc5 and Trpc6. Recent work by Tian et al.
has shown that Trpc5 associates with Rac1 in membrane microdomains, while Trpc6 has a
separate association with RhoA [61]. In response to AT1R stimulation, Trpc5 activation leads to
Rac1 activation and RhoA inactivation. Triggering Trpc6 has the opposite response, with
increased RhoA activity and reduced Rac1 activity. Of note, mutations in the TRPC6 gene have
already been associated with human FSGS [17]. Therefore, this recent study by Tian et al.
provides new insights into how signaling events downstream of the angiotensin receptor may
lead to dynamic cytoskeletal reorganization in podocytes via selective modulation of RhoA and
Rac1 activity through calcium signaling.
Decreased RhoA activity and increased Rac1 activity is associated with proteinuric kidney
disease, consistent with the idea that an imbalance in the RhoA-Rac1 signaling balance is
harmful to the podocyte. HIV infects podocytes and modulates the cytoskeleton of the cell such
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that patients with HIV are susceptible to collapsing FSGS [108]. In podocytes, the HIV adaptor
protein nef interacts with p190RhoGAP that then inactivates RhoA [109]. In addition, nef binds to
diaphanous interacting protein and the Rac1-GEF vav2, resulting in Rac1 activation [110]. Nef
also downregulates synaptopodin expression [111] and may further destabilize RhoA signaling
via the synaptopodin pathway outlined above. The net effect of HIV infection is a downregulation
of RhoA signaling activity and a shift toward Rac1 signaling with consequent podocyte injury.
There is further evidence from mouse models that disrupting the RhoA-Rac1 signaling
balance in podocytes can cause kidney disease. Studies on mice deficient for the Rho-guanine
nucleotide dissociation inhibitor, RhoGDIα (Arhgdia), demonstrate that Rac1 activation in
podocytes is harmful. RhoGDIα binds to and stabilizes Rac1 and RhoA, and, in its absence,
levels of these small G proteins and their activity levels are dysregulated [112]. In particular,
Rac1 is relatively overactivated, leading to podocyte foot process effacement and proteinuria [56,
113]. Interestingly, treatment with a Rac1 inhibitor reduced proteinuria and the severity of the
kidney damage in this model.
Taken together, these studies highlight that the careful control of relative RhoA and Rac1
activity is critical for the proper functioning of podocytes. However, we believe that until this
report a direct regulator of Rac1 activity in response to RhoA signaling had not been described in
podocytes. Here, we show that Arhgap24 is highly expressed in podocytes and inhibits
Rac1-dependent membrane ruffling and epithelial wound healing. Our work predicts that
Arhgap24 would enforce the normal RhoA-dependent nonmotile podocyte phenotype by
inactivating Rac1. Consistent with a role for Arhgap24 in vivo, we identified a mutation in the
38

GAP domain of Arhgap24 in kindred with familial FSGS. This mutation reduces the Rac1-GAP
activity of Arhgap24. We also show that Arhgap24 dimerizes, and this may explain the dominant
pattern of inheritance of the Q158R mutation [114, 115]. Our studies show that Arhgap24 is a
potential candidate gene to explain a subset of inherited FSGS. Perhaps, more informatively,
Arhgap24 adds to the emerging model that aberrant Rac1 activation is a key step in podocyte
dysfunction, leading to proteinuric kidney disease. Since Arhgap24 is selectively expressed in
podocytes, modulating its function can alter relative RhoA/Rac1 activity, with potentially minimal
systemic side effects, and provides an intriguing pathway for the therapy of proteinuric kidney
disease.
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2.6 Tables and Figures
Table 2.1 Incidence of ARHGAP24 nonsynonymous sequence variations in patients with
biopsy-proven FSGS (n=310) and controls (n=180)
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Table 2.2 Non-synonymous SNPs in ARHGAP24
Non-synonymous SNPs identified in the transcript of isoform 1 of ARHGAP24 from over 1000
human genomes sequenced. (www.1000genomes.org) SNPs in bold are known polymorphisms
in the gene.

Table 2.3 Q158 is a conserved residue
Sequence alignment of the Arhgap24 protein across various species in the region of the patient
variation (Q158) shows complete conservation of the glutamine residue.
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Figure 2.1 Differentiated podocytes show reduced membrane ruffling
(A) YFP-actin–transduced podocytes were cultured at the permissive temperature (33°C) or
differentiated for 7 to 14 days at the nonpermissive temperature (37°C). Kymographs (insets)
obtained at the sites of active ruffling (hatched boxes) show prominent ruffling at 33°C that is
reduced at 37°C (also see Supplemental Videos 1 and 2). DIC, differential interference contrast.
Original magnification, ×400; approximately ×1,000 (insets and time-lapse panels). (B)
Quantification of actin spike lengths in kymographs shows that differentiated podocytes (n = 11)
have a significant decrease in ruffling activity compared with that of undifferentiated podocytes
(n = 15). Individual symbols represent data from individual podocytes. P = 3.29 × 10–6 by ANOVA
with post-test correction.
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Figure 2.2 Arhgap24 transcript and Arhgap24 protein are specifically expressed in
podocytes
(A) MBEI values for microarray data for in vitro–cultured podocytes (33°C, 37°C), ex vivo–
isolated podocytes (E13.5, E15.5, and adult), and laser-capture-microdissected glomeruli (E12.5
renal vesicle, E15.5 S-shaped body, and E15.5 renal corpuscle) show an increase in
the Arhgap24 transcript with differentiation in vitro and in vivo. (B) By quantitative RT-PCR,
differentiated podocytes have higher Arhgap24 mRNA levels compared with those of
undifferentiated podocytes, after normalization to 18S rRNA. (C) Immunoblotting shows that
differentiated podocytes have higher levels of Arhgap24 protein than undifferentiated podocytes.
(D) Confocal imaging of cultured podocytes also shows an increase in levels of Arhgap24 in
differentiated podocytes, concentrated in punctate structures at the base of the cell. (E)
Arhgap24 colocalizes with the focal adhesion marker vinculin at the tips of actin stress fibers.
Original magnification, ×600 (D and E).
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Figure 2.3 Arhgap24 is expressed in kidney podocytes in vivo
(A) Immunoblotting of tissue lysates shows that Arhgap24 is expressed in the kidney (expected
size ~95 kD). Smaller bands likely represent specific degradation products. The positive control
(+) is a lysate from HEK293 cells transfected with FLAG-tagged Arhgap24. The negative control
(–) is HEK293 cell lysate. Brn, brain; Kid, kidney; Liv, liver; Lng, lung; Spl, spleen. (B) Magnetic
separation of glomeruli after beating heart perfusion of mice with magnetic beads results in more
than 95% pure isolated glomeruli (top). The flow through consists of tubule fragments (bottom).
Original magnification, ×100. (C) Arhgap24 is enriched in the glomerular (Glom) fraction that also
contains the podocyte protein, podocin. Tub, tubule. (D) A low-magnification view (original
magnification, ×200) of a mouse kidney stained for Arhgap24 shows that the highest signal is
detected in the glomeruli. (E) Within mouse glomeruli, the Arhgap24 signal colocalizes with that
of the podocyte marker synaptopodin. Original magnification, ×600.
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Figure 2.4 Arhgap24 knockdown in differentiated podocytes increases membrane ruffling
(A) Two lentivirally transduced cell lines targeting different portions of the Arhgap24 transcript
show marked reduction of Arhgap24 protein compared with that of an irrelevant knockdown (Fluc,
100%; line 451, 15%; line 756, 40%). Results are representative of at least 3 independent
experiments. (B) Representative images of the 3 knockdown cell lines after differentiation at
37°C for 7 to 10 days. Kymographs (insets) generated from the hatched box area and time-lapse
sequences show that the 2 knockdown cell lines have increased membrane ruffling compared
with that of the control (also see Supplemental Videos 3–5). Original magnification, ×400;
approximately ×1,000 (insets and time-lapse panels). (C) Quantitation of actin spikes in
kymographs shows that both the 451 (n = 19) and 756 (n = 11) Arhgap24 cell lines have
significantly greater membrane ruffling activity compared with that of the control knockdown Fluc
cell line (n = 18) (*P < 0.00001). The ruffling activity is not significantly different between the 2
knockdown cell lines (P = 0.57). Group differences were analyzed by ANOVA with post-test
correction.
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Figure 2.5 Arhgap24 knockdown in differentiated podocytes increases active Rac1 and
Cdc42 levels and accelerates epithelial monolayer wound closure
(A) Pull down of active (GTP-bound) Rac1, Cdc42, and RhoA shows that the Arhgap24
knockdown cell lines (lines 451 and 756) have increased levels of active Rac1 and Cdc42
compared with those of the control (Fluc). However, active RhoA levels are similar across all 3
cell lines. Results are representative of 3 independent experiments. (B) Arhgap24 knockdown
cells migrate and close a scratch made in a confluent monolayer faster than the control
knockdown cell line. Cell nuclei were stained with Hoechst dye. Original magnification ×100.
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Figure 2.6 Pedigree information for T97I and P417A variations
DNAs from one family for the T97I variation and three families for the P417A variation were
available for sequence analysis. The presence of kidney disease (clinical and/or biopsy proven)
is denoted by the filled-in symbols. If DNA was analyzed for sequence variation, the result of a
non-synonymous variation is denoted within the individual symbol (Wt =wildtype; Ht =
heterozygous). The reference protein sequence (NP_001020787) was considered wildtype. In
no instance did the variation consistently correlate with kidney disease.
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Figure 2.7 Individuals with end-stage kidney disease are denoted by black symbols
Deceased family members are represented by diagonal lines. Flanking MSM analysis shows that
the unaffected siblings have a distinct haplotype that is different from that of the affected
individuals. The columns of numbers and letters under each symbol refer to the alleles that
individual carries at the given genetic markers. Where these numbers are within brackets, the
haplotype is inferred. The solid black rectangle beneath individuals 1, 101, and 1001 represents
the inherited disease haplotype.
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Figure 2.8 Arhgap24 Q158R has defective Rac1-GAP activity and dimerizes with the
wild-type protein
(A) Wild-type FLAG-tagged Arhgap24 (first lane) transfected into HEK293 cells reduces active
Rac1 levels compared with Q156R Arhgap24 (last lane). Titration of increasing proportions of
Q156R Arhgap24 produces increased levels of active Rac1 (middle lanes). Total Rac1 and
FLAG-Arhgap24 protein levels are similar across all lanes. Results are representative of 3
different experiments. (B) FLAG- or GFP-tagged wild-type (W) or Q158R Arhgap24 (Q)
constructs were cotransfected into HEK293 cells. Cell lysates were immunoprecipitated with
anti-FLAG antibody and then immunoblotted for GFP-tagged Arhgap24 to assess for protein
dimerization. Whole cell lysates (WCLs) were immunoblotted for GFP and FLAG to ensure
protein expression.
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Chapter 3. Rac1 Activation in Podocytes Induces Rapid Foot Process Effacement
and Proteinuria

3.1 Abstract
The kidney’s vital filtration function depends on the structural integrity of the glomerulus,
the proximal portion of the nephron. Within the glomerulus, the architecturally complex podocyte
forms the final cellular barrier to filtration. Injury to the podocyte results in a morphologic change
called foot process effacement and this is a ubiquitous feature of proteinuria. The exact nature of
foot process effacement is not known but recently it has been proposed that this might reflect
activation of the Rac1 GTPase. To test this hypothesis, we generated a podocyte specific,
inducible transgenic mouse line that expressed constitutively active Rac1. We observed a rapid
onset of proteinuria that began to remit spontaneously in one week. Using super resolution
imaging, we verified that the induced transgene was expressed in damaged podocytes. The
kinetics of this podocyte injury model differs from previously reported studies and highlights the
complex balance of Rho-GTPase signaling that is required for proper regulation of the podocyte
cytoskeleton.

3.2 Introduction
The structural integrity of the proximal portion of the nephron, the glomerulus, is vital to the
kidney’s filtration function. Within the glomerular capillary tuft, the kidney’s filtration barrier is a
biomechanical composite of fenestrated endothelial cells, a thick glomerular basement
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membrane and complex visceral epithelial cells called podocytes. Podocytes lie on the outer
aspect of glomerular capillaries and extend cytoplasmic processes (foot processes) that
interdigitate with those from neighboring podocytes to form a mesh-like network that forms the
final barrier to filtration. Podocyte foot processes are built around highly organized actin bundles
that are reorganized during injury with flattening and simplification (“effacement”) of foot
processes leading to spillage of serum proteins into the urine (proteinuria). Defects in actin
regulatory

proteins

lead

to

irreversible

podocyte

injury

and

focal

and

segmental

glomerulosclerosis (FSGS) in humans and in animal models [2].
Recent studies show that rather than being a static filter, the cytoskeleton and therefore the
shape of the podocyte are both tightly regulated and dynamic [52]. Small GTPases of the Rho
family (exemplified by RhoA, Cdc42, Rac1) are the central organizers of the actin cytoskeleton
[48]. After receiving diverse signaling inputs, the Rho-family of small GTPases act through their
effectors to polymerize and organize actin filaments into various configurations that deform the
cell membrane and change cell shape. Of the three major Rho-family GTPases, Cdc42 has been
shown to be critical for podocyte development, while both RhoA and Rac1 seem dispensable in
early stages [28].
After this initial phase, RhoA and Rac1 seem to play more important roles in podocyte cell
biology. In many biological systems, including podocytes, RhoA and Rac1 antagonize each
other’s activation and function [50, 116]. Recent studies have shown that constitutive activation
of RhoA causes podocyte foot process effacement and proteinuria after several weeks [49, 117],
suggesting that inappropriate RhoA activation is pathogenic to podocytes. This is surprising
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given that 1) activation of Rho family GTPases causes rapid cytoskeletal rearrangement in vitro
[118, 119]; and 2) introduction of dominant-negative RhoA produces a similar phenotype [49].
On the other hand, it has been proposed that excessive Rac1 activation or inhibition of Rho
activity might be the key step in podocyte injury. Synaptopodin, a podocyte actin-binding protein,
reinforces RhoA signaling and suppresses Cdc42 signaling to promote proper cytoskeletal
architecture [59, 120]. Genetic ablation of synaptopodin in mice results in increased susceptibility
to proteinuria [60, 121]. Deletion of RhoGDI (a negative regulator of Rho-family GTPases) in
mice results in foot process effacement and proteinuria that correlates with increased Rac1
activity [56]. Mutations in the GTPase activating protein Arhgap24 result in increased Rac1
activation in vitro and are correlated with podocyte injury and FSGS in patients [122].
The effects of Rac1 activation in podocytes have only been studied indirectly through the
manipulation of upstream regulatory proteins [21, 56, 122, 123]. To test directly whether Rac
activation induces podocyte foot process effacement, we generated a double transgenic system
in mice in which GFP-tagged constitutively active Rac1 (Rac1Q61L) is expressed in podocytes
after doxycycline (DOX) induction. We observed rapid onset of proteinuria within 2 days of DOX
induction. The degree of proteinuria correlated with the levels of active Rac1 expression.
However, proteinuria in this system was not durable and gradually decreased over the course of
a month despite continuous exposure to DOX. Thus, activation of Rac1 in podocytes rapidly
causes foot process effacement and proteinuria in vivo. These results are distinct from the
effects of RhoA activation in podocytes and emphasize the complex interplay of small GTPase
signaling in the regulation of podocyte shape and function.
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3.3 Methods
3.3.1 Generation of EGFP_CA-Rac1 knock-in transgenic mice
We chose the X-linked Hprt1 locus for targeting because it is a nonessential housekeeping
gene that encodes a selectable marker [124, 125]. The pHPRT targeting vector was generated
on a pBluescript SKII(-) backbone by PCR amplifying the left arm (5.1 kb fragment upstream of
Exon 1) and right arm (2.1 kb fragment downstream of Exon 1) of the Hprt1 gene from a bacterial
artificial chromosome (RP24-335G16). The tetracycline responsive promoter element (TRE),
EGFP, Rac1Q61L, and bovine growth hormone polyadenylation signal (bGH-polyA) sequences
were amplified by PCR, and inserted sequentially into the pHPRT targeting vector. The KH2 ES
cell line harboring the Rosa26-M2rtTA insertion was used for transfection. Cells with homologous
recombination of the transgene into the Hprt1 locus were selected based on their growth in the
presence of 6-thioguanine, which is toxic to cells expressing functional Hprt1. Appropriate single
copy insertion of the EGFP_CA-Rac1 transgene into the Hprt1 locus was confirmed by PCR.
Targeted ES cells were injected into blastocysts to generate chimeric mice. EGFP genotyping
primers

(a

protocol

(Forward_oIMR0872

from

The

Jackson

Laboratory)

were

5’-AAGTTCATCTGCACCACCG-3’,

5’-TCCTTGAAGAAGATGGTGCG-3’;

internal

positive

control

5’-CTAGGCCACAGAATTGAAAGATCT-3’,

used

for

genotyping

Reverse_oIMR1416
Forward_oIMR7338
Reverse_oIMR7339

5’-GTAGGTGGAAATTCTAGCATCATCC-3’). All animal experiments were conducted with
approval of the Washington University Animal Studies Committee.
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3.3.2 Mouse strains and transgene induction
The Rosa26-rtTA mouse strain was purchased from The Jackson Laboratory (#006965).
The NPHS2-rtTA strain was obtained from Dr. Jeffrey Kopp at the NIH. The Nphs1-rtTA-3G
strain will be described in detail elsewhere [126]. All mice used in this study were male and
therefore carried a single copy of the EGFP_CA-Rac1 transgene. To induce transgene
expression, regular chow was substituted with DOX-supplemented chow (2000ppm, TestDiet)
for the indicated time periods.
3.3.3 Cell culture and cell based assays
Immortalized murine podocytes were maintained and differentiated as described
previously [122]. For live cell imaging assays, podocytes were infected with lentiviral vectors
encoding N-terminal EGFP tagged CA-Rac1 and CA-RhoA. An EGFP empty vector was used as
control.
3.3.4 Antibodies
Antibodies for immunostaining included rabbit anti-podocin (Sigma Aldrich P0372, 1:400 dilution),
goat anti-nephrin (R&D Systems AF3159, 1:100 dilution), rabbit anti-laminin β2 (20) (1:1500
dilution) and chicken anti-GFP (Invitrogen A10262, 1:500 dilution). Antibodies used for
immunoblotting were mouse anti-GFP (Clontech 632381, 1:10000 dilution), rabbit anti-ERK2
(Santa Cruz Biotechnology sc-154, 1:5000 dilution) and rabbit anti-podocin (Sigma-Aldrich
P0372, 1:500 dilution). Fluorescently-conjugated secondary antibodies were purchased from
Jackson Immunoresearch, and the STORM antibodies were conjugated as described [127].
3.3.5 Immunofluorescence assays
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Fresh kidney tissue was embedded in OCT compound and snap frozen on dry ice. 8 µm
cryosections were applied to charged slides. Cultured podocytes were seeded onto collagen I
coated coverslips. For immunofluorescence assays, the tissue sections or coverslips containing
podocytes were fixed with 1% PFA in PBS for 5 minutes followed by blocking and
permeabilization with 2% FBS in PBS with 0.1% saponin. Primary antibodies at the indicated
dilutions were applied for 1 hour at room temperature. After extensive washes, fluorescently
conjugated secondary antibodies were applied at 1:500 dilution for another hour at room
temperature. After washing, the prepared slides were imaged on a Olympus FV-1000 spinning
disc confocal microscope.
3.3.6 Albumin/creatinine assay
Mouse urine samples were collected at the indicated time points and urinary albumin
(Bethyl, E90-134) and creatinine (BioAssay Systems, DICT-500) were quantified by ELISA
according to the manufacturers’ protocols.
3.3.7Transmission Electron Microscopy
Portions of kidney cortex were fixed with 2% paraformaldehyde and 2% glutaraldehyde
and processed for electron microscopy. Ultrathin sections were prepared and imaged by the
Electron Microscopy Core Facility at Washington University.
3.3.8 STORM imaging and STORM-SEM correlation
Kidney tissues were fixed in 4% paraformaldehyde and cryoprotected in 30% sucrose.
Tissues were then embedded in OCT compound and semi-thin sectioned at 100-200 nm
thickness using an ultra cryomicrotome. These tissue sections were collected on a
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carbon-coated #1 coverslip and fixed and stained as described previously [127]. Using a custom
STORM microscope, 20,000 imaging cycles were collected and the resulting images were
compiled to generate a composite multi-channel image as described earlier [128]. After STORM
imaging, the coverslip was floated off and the sample was fixed with 2% glutaraldehyde. This
sample was then processed for scanning electron microscopy (SEM). The images obtained from
STORM and SEM were superimposed using Photoshop CS5.1.
3.3.9 Live cell imaging and kymograph analysis
Undifferentiated murine podocytes were transiently transfected using Amaxa Nucleofection
(Lonza, Allendale, NJ) with plasmids encoding for constitutively active Rac1 or RhoA.
Transfected podocytes were cultured on collagen I-coated glass-bottomed dishes overnight, and
serum starved for 6 hours to arrest baseline membrane ruffling. Rac1 transfected podocytes
were imaged in the serum starved state, while Rho transfected podocytes were imaged following
the addition of 10% FBS 10 minutes prior to imaging to induce membrane ruffling. Sequential
images were obtained by an Olympus FluoView FV1000 microscope every 10 seconds for a
20-minute duration, and movies assembled using Olympus Fluoview software. The ImageJ
plug-in, Multiple Kymograph (http://rsbweb.nih.gov/ij), was used to generate kymographs at 5
different locations of maximum membrane ruffling for each imaged cell [100]. 10 actin spikes
were measured for each kymograph, and average length (ruffling index) was determined as
previously described [100].
3.3.10 Rac1 pull-down assay
The GST-tagged Pak1-PBD was expressed in BL21(DE3) E. coli and purified using
57

glutathione-agarose beads. For the active Rac1 pull-down assay, whole kidney lysates were
generated by homogenizing the kidneys in cell lysis buffer (50mM Tris-HCl, pH7.5, 150mM NaCl,
5mM MgCl2, 10% Glycerol, 1% NP-40, 1mM DTT, 1mM PMSF, 10µg aprotinin, 10µg leupeptin;
aprotinin, leupeptin, DTT and PMSF are fresh added), and isolating the supernatant. Equal
volumes of the lysates were incubated with GST-PBD beads. Rac1-GTP bound to the beads
(active Rac1) was eluted with Laemmli sample buffer and examined by western blot.

3.4 Results
3.4.1 Rho family GTPases induce distinct effects on the actin cytoskeleton in cultured murine
podocytes
A network of highly organized actin cytoskeleton structures forms the structure of podocyte
foot processes. During podocyte foot process effacement, these actin bundles are reorganized
into broad membrane sheets that resemble lamellipodia seen in cultured cells. Numerous cell
culture systems point to a critical role for Rho family GTPases in actin cytoskeleton remodeling
with RhoA activation inducing actin bundling and Rac1 activation inducing lamellipodia [48].
Therefore, we hypothesized that the remodeling of the podocyte actin cytoskeleton seen during
the process of effacement may represent an alteration in the balance between Rac1 and RhoA
activities [122].
To test the effects of Rho GTPase activation on the podocyte actin cytoskeleton in vitro, we
first transfected a murine immortalized podocyte cell line with enhanced green fluorescent
protein (EGFP) fused to constitutively active versions of Rac1 (EGFP_CA-Rac1) and RhoA
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(EGFP_CA-RhoA). Actin fibers and focal adhesions were visualized with phalloidin and vinculin
respectively. Constitutively active Rho (CA-Rho) increased the number of stress fibers and focal
adhesions in podocytes (Figure 3.1A). In contrast, CA-Rac1 expression in podocytes induced
membrane spreading and lamellipodia formation resulting in large, round and flattened cells
(Figure 3.1A).
Since foot process effacement might be an expression of podocyte motility [93], we next
asked if these changes in cell morphology correlated with changes in podocyte membrane
dynamics. Using live cell imaging, we quantitated membrane motility using kymograph analysis
as described previously [122]. Podocytes expressing CA-Rac1 show increased membrane
ruffling compared with wild type cells after serum starvation (Figure 3.1B, and Videos S1 and S2).
Addition of serum induced membrane ruffling in wild type cells, and this was largely suppressed
in podocytes expressing CA-RhoA (Figure 3.1C, and Videos S3 and S4). These experiments
confirmed that activation of Rac1 and RhoA produce marked changes in the podocyte actin
cytoskeleton and on membrane dynamics. Active Rac1 induced lamellipodia formation and
increased membrane motility in podocytes, while active RhoA stabilized the cytoskeleton and
suppressed membrane motility.
3.4.2 Generation of inducible EGFP_CA-Rac1 transgenic mice
Our in vitro results suggested that Rac1 activation might have significant effects on
podocyte morphology. This is in contrast to recent studies that showed RhoA activation could
play a pathogenic role in podocytes in vivo [49, 117]. To test the effects of Rac1 activation in
podocytes in vivo, we generated a transgenic mouse model that would allow for inducible
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EGFP_CA-Rac1.

Using

homologous

recombination,

we

targeted

the

EGFP_CA-Rac1 transgene into the Hprt1 locus in ES cells [124, 125] (Figure 3.2A) containing
the tetracycline inducible transactivator (rtTA) inserted into the Rosa26 locus (Rosa-rtTA) [129].
Cells with successful homologous recombination of the transgene for the Hprt1 locus were
selected based on their growth in the presence of 6-thioguanine, which is toxic to cells harboring
a functional Hprt1 allele. Targeted gene insertion was confirmed by PCR (Figs. 2 B and C) and
recombinant ES cells were microinjected into blastocysts to generate chimeric mice.
To test inducible expression of the EGFP_CA-Rac1 transgene, mice were fed doxycycline
(DOX) for one week, and multiple tissues were harvested and examined for EGFP expression by
fluorescence microscopy (Figure 3-S1). DOX induced strong transgene expression in multiple
tissues. However, we could not detect EGFP expression in podocytes by fluorescence
microscopy. These experiments revealed that the Rosa26-rtTA allele was ineffective at driving
efficient transgene expression in podocytes.
3.4.3 EGFP_CA-Rac1 expression in podocytes causes rapid onset but transient proteinuria
To induce podocyte-specific expression of the CA-Rac1 transgene, we crossed our mice
with transgenic mice with the rtTA driven by the human podocin promoter (NPHS2-rtTA) [130]. In
double transgenic mice (PODxRac1) fed DOX, EGFP expression was detectable as early as 4
days after induction. To validate the functionality of the CA-Rac1 transgene product, we used the
p21 binding domain of PAK1 (PBD) to precipitate CA-Rac1 from whole kidney lysates of
DOX-treated double transgenic mice (Figure 3.2D). EGFP_CA-Rac1 protein was easily
detectable in the DOX-treated mice but was undetectable in the absence of DOX. Expression of
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the transgene was barely detectable in the whole kidney lysate, which was not surprising given
that podocytes constitute only a small fraction of cells in the kidney. Expression of the CA-Rac1
transgene in podocytes was confirmed by colocalization with the podocyte-specific marker
(podocin) by immunofluorescence microscopy (Figure 3.3A). Surprisingly, the CA-Rac1
transgene was expressed in only a small fraction of podocytes, and this expression was variable
between glomeruli and between mice.
After 2 days of induction with DOX, however, PODxRac1 mice developed significant
proteinuria compared to single transgenic control mice. Proteinuria reached its peak on day 4
and then began to abate around 1 week post-induction (Figure 3.3B, and 3-S2). DOX treatment
for up to one month did not result in progressive renal dysfunction or significant histologic
alterations. Given the variable expression of the transgene, we assessed whether the level of
proteinuria correlated with the level of expression (Figure 3.3C). The magnitude of proteinuria
positively correlated with the frequency of EGFP-positive glomeruli. The kinetics of proteinuria,
however, were similar among all PODxRac1 mice beginning around day 2 and abating after day
7 (Figure 3-S2). These experiments showed that podocyte-specific expression of CA-Rac1
induces rapid and transient proteinuria that correlated with the level of transgene expression.
3.4.4 Nphs1-rtTA-driven EGFP_CA-Rac1 expression in podocytes results in higher transgene
expression and more severe proteinuria
We considered that the patchy and uneven expression of CA-Rac1 might be due to issues
with silencing of the NPHS2-rtTA transgene. To circumvent this problem, a new transgenic
mouse line (NEF) expressing a modified rtTA (rtTA-3G) under the control of the mouse nephrin
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(Nphs1) promoter was generated [126] and bred to our CA-Rac1 mice. Examination of kidneys
from double transgenic (NEFxRac1) mice after four days of DOX treatment showed a greater
proportion of glomeruli and higher numbers of podocytes expressing the transgene compared to
the PODxRac1 mice. Yet, the expression in podocytes was still not 100% (Figure 3.4A). This
increased expression and distribution of the CA-Rac1 transgene correlated with a faster onset
and higher levels of proteinuria (Figure 3.4B). In contrast to PODxRac1 mice, the proteinuria in
NEFxRac1 mice persisted after one week of DOX treatment (Figure 3.4C, 3-S2). However,
similar to PODxRac1 mice, proteinuria peaked at day 4 and gradually decreased over time
(Figure 3.4C). After exposure to DOX for 28 days, we could not detect any EGFP expressing
podocytes in kidney sections suggesting that the transgene-positive podocytes had been lost
(Figure 3.5B).
3.4.5 EGFP_CA-Rac1 induces foot process effacement, but without other histological changes in
the glomerulus
The morphology of podocytes expressing CA-Rac1 was assessed by both light and
electron microscopy. Glomeruli from DOX-induced Rac1 single transgenic mice and NEFxRac1
mice were unremarkable by light microscopy (Figure 3.5A). No obvious abnormalities were
detected even after 1 month of continuous DOX induction. Transmission electron microscopy
showed segmental effacement of podocyte foot processes in PODxRac1 glomeruli (Figure 3.6A)
consistent with variable transgene expression. To test this, we used a super resolution
fluorescence imaging method, Stochastic Optical Reconstruction Microscopy (STORM). STORM
allows nanometer resolution of fluorescently tagged molecules such as labeled antibodies by
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capturing thousands of sequential images of a specimen illuminated with a very low energy
excitation source [127]. Sections of kidney tissue from NEFxRac1 mice on day 4 after DOX
induction was stained with fluorescently tagged antibodies for EGFP (to localize CA-Rac1) and
laminin β2 (to detect the glomerular basement membrane) and examined by STORM. After
STORM imaging, the same tissue sample was processed for freeze etch electron microscopy
and the images were correlated (Figure 3.6 B and C). This showed that only the EGFP_CA-Rac1
expressing podocytes had effaced foot processes, while adjacent non-expressing podocytes had
intact foot processes (Figure 3.6C). These studies provide an explanation for the segmental foot
process effacement seen by TEM.
3.4.6 CA-Rac1 decreases podocin and nephrin levels via proteasomal degradation
During our examination of the kidney with immunofluorescence microcsopy, we noted that
in both PODxRac1 and NEFxRac1 mice CA-Rac1 expression was inversely correlated with
podocin and nephrin level (Figure 3.7 A and B). Quantitative correlation of EGFP pixel intensity
with that of podocin and nephrin showed a significant negative correlation (Figure 3.7 C, D, E
and F). To test whether Rac1 activation cause a direct downregulation of podocin expression,
cultured podocytes were transiently transfected with empty vector, EGFP_CA-Rac1 and
EGFP_CA-RhoA, and podocin levels were analyzed by immunoblotting. Compared with the
vector control, CA-Rac1 diminished podocin levels by about 50%, while CA-RhoA had no effect
(Figure 3.7G). We measured the levels of podocin mRNA in these podocytes by quantitative
PCR and found no significant difference, which suggested that the podocin decrease was not
mediated by transcriptional downregulation (Figure 3-S3). The decrease in podocin levels could
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be blocked by the proteasome inhibitor MG132, suggesting that Rac1 activation induces podocin
degradation via a proteasomal pathway (Figure 3.7H).
3.4.7 CA-Rac1 expression stimulate membrane dynamics in podocytes in vivo
To further investigate that CA-Rac1 expressing podocytes in vivo, we used multiphoton
intravital imaging (MPM) technique to directly assess podocyte membrane dynamics in live mice.
Since CA-Rac1 is tagged with EGFP at the N-terminus and only some of the podocytes
expressed this transgene after DOX induction, we could directly observe EGFP+ podocyte
membrane dynamics. Dylight594-labeled lectin molecules were injected intravenously before
imaging. Endothelial cells and Tubular epithelial cells can absorb lectin and be labeled in the red
channel. During the imaging process, each frame was taken at 30-second time interval by using
resonance scanner. We observed dramatic membrane dynamics in EGFP_CA-Rac1+ podocytes
(Figure 3.8). Our result suggests that CA-Rac1 induce membrane ruffling in podocytes in vivo.
The membrane ruffling is likely caused by actin cytoskeleton rearrangement induced by high Rac
activity.
3.4.8 The shattered podocytes could from new interaction with the interstitial endothelium in the
renal tubules
In our intravital imaging experiments, we observed EGFP+ cells that formed stable
interaction with the renal tubules (Figure 3.9). Because the expression of rtTA transgene is
restricted to podocytes [126], these cells could be podocytes that shattered from the glomerulus.
Surprisingly, 3D images of these cells showed that they establish stable interactions with the
epithelial cells in the tubules (Figure 3.9). Some of these cells extended protrusions that crossed
64

the basement membrane of the tubular epithelium and formed new interactions with the
endothelial cells of the interstitial capillaries. This result suggests that high Rac activity could
cause podocyte shattering from the glomerulus. However, shattered podocytes could form new
connections with other endothelial cells outside the glomerulus.

3.5 Discussions
The structural integrity of the glomerular filtration barrier is essential for selective excretion
of waste products and the retention of cells and large serum proteins within the circulation. The
glomerular podocyte, with its arbor of interdigitating foot processes, is the critical final component
of the kidney’s filtration barrier. The elaborate actin-based cytoskeleton of the podocyte’s foot
process is simplified in many diseases in which serum proteins are lost into the urine. Since actin
reorganization mediated by Rho family GTPases is a well-established mechanism for cell shape
change, we and others have attempted to directly ask how specific Rho GTPase activation
regulates podocyte morphology in vivo.
Previous studies used an approach similar to ours to study the role of RhoA in podocytes.
Both constitutively active and dominant negative (DN) inducible RhoA transgenic mouse lines
were generated [49, 118]. While both approaches resulted in podocyte dysfunction, the changes
detected occurred relatively slowly, over weeks to months. Given how rapidly Rho family
GTPases induce actin cytoskeletal changes in vitro, it raises the possibility that proteinuria in
those systems is due to indirect effects of transgene expression in podocytes and not due to a
direct signaling effect of RhoA. In addition, the mechanism of foot process effacement directed
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by RhoA activation was not directly addressed in these studies.
In our mouse, expression of constitutively active Rac1 (CA-Rac1) produced rapid onset (~48
hours) proteinuria that correlated with the degree of transgene expression. While the Nphs1-rtTA
transgene was expressed in a larger percentage of podocytes than the NPHS2-rtTA transgene,
neither driver promoted expression in all of the cells. This was supported by our finding of
segmental foot process effacement detected by electron microscopy. Using STORM imaging
and freeze-etch electron microscopy correlation techniques, we confirmed that effaced foot
processes correlated with GFP positive cells, while the foot processes of podocytes not
expressing the transgene remained intact [128]. The rapid onset and dose-responsive nature of
proteinuria induced by CA-Rac1 expression provides strong evidence for a direct signaling role
for Rac1 activation in generating foot process effacement. This in vivo biologic correlate further
supports the use of the membrane-ruffling assay in cultured podocytes as a useful reporter of
podocyte injury in vitro. Our results demonstrate for the first time that Rac1 activation in
podocytes can directly cause foot process effacement and proteinuria.
While onset of proteinuria in the CA-Rac1 expressing mice was rapid, the proteinuria
induced was only transient. As GFP could not be detected in kidneys of mice treated long-term
with DOX, we suspect that chronic Rac1 activation is toxic to podocytes. The efficiency of
CA-Rac1 transgene expression differed between the two different rtTA driver lines and therefore
incomplete CA-Rac1 expression is related in part to the efficiency of the promoter driving rtTA
expression. It is well-known that epigenetic silencing can suppress transgene expression over
time [131]. It is also possible that the incomplete expression of our CA-Rac1 transgene may be
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related to other epigenetic factors that can affect expression of both the driver and CA-Rac1
transgenes.
We did not observe any progressive renal dysfunction or focal and segmental
glomerulosclerosis (FSGS) in the CA-Rac1 expressing mice after prolonged DOX treatment, in
contrast to the CA-RhoA transgenic mice [118]. This may be attributed to the low frequency of
EGFP_CA-Rac1-expressing podocytes in our systems, since in a rat model of tunable podocyte
loss, approximately 20 to 40% podocyte depletion was required before FSGS was consistently
observed [26].
The presence of CA-Rac1 reduced podocin protein expression both in vivo and in cultured
podocytes. This was mediated, at least in part, by proteasomal degradation as it could be
blocked in vitro with proteasome inhibitors. Because we could not detect CA-Rac1-positive cells
after extended DOX treatment, we suspect that the expressing podocytes were eliminated and
replaced either by remaining podocytes or by a progenitor population [126, 132]. These
compensatory mechanisms might explain the resolution of proteinuria over time in the CA-Rac1
expressing mice. Therefore, future studies should focus on the development of tools to detect
activation of endogenous Rac1 and RhoA in podocytes. The balance and localization of the
activity of these GTPases is likely to be tightly and dynamically regulated for proper podocyte
function.
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3.6 Figures

Figure 3.1 Constitutively active Rho family GTPases exert opposing effects on the actin
cytoskeleton of podocytes
(A) Immunofluorescence imaging was performed on differentiated mouse podocytes that were
stably transduced with EGFP_CA-Rac1 or EGFP_CA-RhoA (green). The filamentous actin
network was delineated with phalloidin (red) and focal adhesions and contacts were identified
with vinculin (blue). Compared to control, untransduced cells, EGFP_CA-Rac1 induced flattening
of the cell and lamellipodia formation while EGFP_CA-RhoA induced numerous stress fibers and
cell contraction. (B) EGFP_CA-RhoA suppresses serum-induced membrane ruffling in
podocytes. Left panel, using kymographic analysis, under conditions of serum starvation,
podocytes exhibit minimal membrane ruffling activity. Introduction of EGFP_CA-Rac1
significantly increases membrane dynamics and ruffling (*** P< 0.0001 by unpaired T-test). Right
panel, exposing starved cells to serum also induces membrane ruffling which is suppressed by
introduction of EGFP_CA-RhoA (*** P< 0.0001 by unpaired T-test).
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Figure 3.2 Generation of inducible EGFP_CA-Rac1 transgenic mice
(A) Strategy for targeted insertion of an inducible EGFP_CA-Rac1 into Exon 1 of the murine
Hprt1 locus on chromosome X. The tetracycline response element (TRE) allows for DOX
inducible EGFP_CA-Rac1 expression when crossed to lineage-specific rtTA-transgenic mouse
lines. (B) Confirmation of targeted insertion and verification of EGFP_CA-Rac1 activity in
transgenic mice. Long genomic PCR for the 5’ and 3’ insertion sites confirmed homologous
recombination in ES cell clone 36 (parental KH2 ES cells are used as the negative control).
Lanes 1 and 3: Primer1 (in 5’ EGFP transgene sequence) and Primer3 (400bp down stream of
the 3’ arm). Lanes 2 and 4: genomic PCR by Primer2 (in Rac1 transgene sequence) and Primer3.
(C) XbaI digestion produced specific digestion bands (400bp and 600bp) that confirmed the
specificity of the 5’ and 3’ targeted locus PCR products from Figure 3.2B. Two replicates are
shown. (D) Transgenically expressed EGFP_CA-Rac1 is functionally active. EGFP_CA-Rac1
transgenic mice were crossed to NPHS2-rtTA inducer mice to generate PODxRac1 mice.
EGFP_CA-Rac1 transgene was induced by feeding DOX to the mice. Transgenically expressed
EGFP_CA-Rac1 binds to GST-PBD, which specifically recognizes the active conformation of
Rac1. Transgenic EGFP_CA-Rac1 is not induced and is not present to bind to GST-PBD without
DOX induction. Representative data from two induced and non-induced PODxRac1 mice are
shown.
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Figure 3.3 Podocyte specific expression of CA-Rac1 causes proteinuria
(A) Upper panels, without DOX induction, EGFP_CA-Rac1 is not expressed in PODxRac1 mice.
Lower panels, after a 4-day DOX induction, EGFP_CA-Rac1 transgene (green) is specifically
expressed in glomerular podocytes, confirmed by immunofluorescence colocalization with the
podocyte marker, podocin (red). (B) DOX treatment induced fast onset of proteinuria in
PODxRac1 mice. Urine samples were collected at the indicated timepoints from the single
transgenic EGFP_CA-Rac1 and DOX induced double transgenic PODxRac1 mice at the
indicated timepoints. Proteinuria was quantitated by measuring the albumin/Creatinine ratio
(Al/Cr) for each sample. Each point represents the Al/Cr ratio from a single mouse measured at
the indicated timepoints. (C) The frequency of EGFP+ glomeruli correlated positively with the
level of proteinuria (Al/Cr ratio) (Pearson’s r=0.8831, P< 0.0001).
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Figure 3.4 EGFP_ CA-Rac1 expression driven by Nphs1-rtTA induces more robust
transgene expression and transient proteinuria
(A) Nphs1-rtTA mice were generated and crossed to EGFP_ CA-Rac1 transgenic mice to
generate NEFxRac1 mice. After 4 days of DOX treatment, there was robust expression of the
EGFP_CA-Rac1 transgene (green) in podocytes, labeled with the podocyte marker, podocin
(red). (B) As before, NEFxRac1 mice were treated with DOX for various time periods and
proteinuria was measured in the collected urine samples. Compared to the single transgenic
(EGFP_CA-Rac1 only) control, NEFxRac1 mice exhibit significant proteinuria as early as 2 days
after induction. Each point represents the Al/Cr ratio from a single mouse measured at the
indicated timepoints. (C) Similar to PODxRac1 mice, the proteinuria in NEFxRac1 mice peaks
around day 4 and then returns to baseline in 28 days. Each point represents the Al/Cr ratio from
a single mouse measured at the indicated time points.
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Figure 3.5 No obvious pathological changes were detected in histological analysis, and
the transgene positive podocytes were lost after prolonged DOX treatment
(A) hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) stained kidney sections from
NEFxRac1 mice induced with DOX for 4 days. The control kidney samples are shown on the left,
and the NEFxRac1 tissues are shown on the right. (B) The kidney samples were harvested from
3 NEFxRac1 treated by DOX for 4 days or 28 days. For each kidney sections, the percentage of
EGFP+ positive glomeruli was counted.
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Figure 3.6 EGFP_CA-Rac1 expression in podocytes is associated with foot process
effacement in vivo
(A) Left panel, examination of kidney tissues from DOX treated PODxRac1 mice by transmission
electron microscopy demonstrates segmental effacement (E) of podocyte foot processes while
the foot processes of neighboring podocytes are intact and appear normal (N). The panels on the
right demonstrate the same areas at higher magnification. (B) Scanning electron microscopy
(SEM, left panel) and STORM (right panel) imaging techniques were performed on the same
glomerulus from a NEFxRac1 mouse treated with DOX for 4 days. For STORM imaging, the
sample was stained for laminin β2 (red) and EGFP (green) to label EGFP_CA-Rac1 expressing
podocytes. The boxed area is examined in detail in Figure 3.4C. (C) Correlation of STORM and
SEM images identifies that EGFP-CA-Rac1 expressing podocyte have effaced foot processes
while neighboring, non-transgene expressing podocytes retain intact foot processes. The left
panel shows capillary loops with effaced foot processes (arrowheads) and intact foot processes
(arrows). The middle panel presents the STORM imaging of the same area with laminin β2 (red)
and EGFP (green). The right panel shows a schematized representation of the STORM data
overlaid on the SEM image. The glomerular basement membrane marked by laminin 2 is
outlined in red. The EGFP_CA-Rac1 podocyte with its effaced foot processes is outlined in green.
The intact foot processes of non-transgene expressing podocytes are outlined in blue.
(M-mesangial cell, En-endothelial cell)
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Figure 3.7 EGFP_CA-Rac1 expression correlates with reduced expression of podocin and
nephrin
A NEFxRac1 mouse was induced with DOX for 4 days and glomeruli were stained for nephrin (A)
and podocin (C), both shown in red. There is decreased expression of nephrin and podocin in
podocytes expressing the EGFP_CA-Rac1 transgene. Quantitation of pixel intensity across the
glomerulus demonstrates separation of nephrin (B, Pearson’s r= -0.3840, P< 0.0001) and
podocin (D, Pearson’s r= -0.1432 P< 0.0001) signals compared to EGFP_CA-Rac1 signals.
Additional measurement of three other glomeruli are shown in (E, nephrin) and (F, podocin). (G)
EGFP_CA-Rac1, but not EGFP_CA-RhoA expression in cultured podocytes reduces podocin
protein levels. Left panel, cultured podocytes were electroporated with EGFP_CA-Rac1 or
EGFP_CA-RhoA expression plasmids. Protein lysates were immunoblotted for podocin, Erk2
and EGFP. Compared to the empty vector control and EGFP_CA-RhoA, EGFP_CA-Rac1
reduced podocin protein levels. Right panel, densitometric quantitation of three independent
experiments normalized to Erk2 levels. * P< 0.05 by unpaired t-test. (H) The reduction of podocin
levels can be rescued by treatment with the proteasomal inhibitor MG132, but not with vehicle
(DMSO) alone.
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Figure 3.8 Time-lapse intravital MPM imaging of DOX induced NEFxRac1 mice
Here shows nine images of the same glomerulus in 32 minutes of intravital MPM imaging
experiment. The green channel is EGFP_CA-Rac1 positive podocytes. The red channel shows
the capillaries in the glomerulus. The blue channel shows second harmonic signal from collagen
matrix. The white arrow shows the membrane dynamics of the podocytes over time.
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Figure 3.9 Z-stack images of EGFP_CA-Rac1+ podocyte that attach to the epithelium of
the renal tubules
The green channel is EGFP_CA-Rac1 positive podocytes. The red channel shows the tubular
epithelium and interstitial capillaries that obsorbed Dylight594-labelled lectin. The images were
generated from a 3D image file.

77

Figure 3.10 EGFP_CA-Rac1+ podyctes extended protrusions that penetrates the tubular
epithelium and touched the basal side of the interstitial endothelial cells
The green channel is EGFP_CA-Rac1 positive podocytes. The red channel shows the tubular
epithelium and interstitial capillaries that obsorbed Dylight594-labelled lectin. The arrows show
an interstitial capillary. L: the lumen of a renal tubule. P: podocytes that express
EGFP_CA-Rac1.
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Chapter 4. A Role for Genetic Susceptibility in Sporadic Focal Segmental
Glomerulosclerosis

4.1 Abstract
Focal segmental glomerulosclerosis (FSGS), a disease of kidney podocytes is a significant
cause of chronic kidney disease. FSGS can be caused by multiple factors including genetics,
medication toxicity, obesity, inflammation and viral infection. In the fraction of FSGS subjects with
a family history, highly penetrant disease genes have been identified. The identification of
APOL1 as a susceptibility factor for FSGS in African Americans with HIV suggests that genetic
factors may play a broader role in enhancing susceptibility to FSGS. Here we used sequencing
to investigate whether genetics plays a role in the majority of FSGS cases called primary or
sporadic FSGS where medications and viruses have been ruled out as causes. We identified 16
potential new FSGS genes and found that over 46% of FSGS subjects may carry susceptibility
genetic variants. Using a novel mouse method based on the manipulation of a murine embryonic
stem cell line with a genetic background susceptible to FSGS, we validated three of the top four
FSGS candidate genes. Our work supports the feasibility of studying the role of genetic
background in the susceptibility to disease in humans.
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4.2 Introduction
The glomerulus of the kidney is a specialized capillary bed that generates an ultrafiltrate
that after modification by the kidney tubule system becomes urine. Diseases of the glomerulus
often lead to chronic kidney disease, a major health care problem affecting between 5-10% of the
adult population in developed countries [3]. Treatment options are limited, in part owing to the
poor understanding of the pathogenesis of disease. Better insights into the root cause of disease
offer hope for eventual improvement of this situation.
One of the most common glomerular syndromes is focal segmental glomerulosclerosis
(FSGS). The pathologic change of FSGS is a scar that develops focally (in some but not all
glomeruli) and segmentally (in only part of a glomerulus). While originally considered a disease,
FSGS is now thought to consist of a variety of different syndromes. These include primary
(idiopathic) FSGS that is thought to be caused by a circulating factor and secondary FSGS,
which may be caused by viruses, medications and genetic mutations. The most common form of
secondary FSGS follows glomerular hyperfiltration arising from mismatch between metabolic
load and glomerular capacity, associated with obesity, low birth weight, reduced renal mass as
well other causes. Genetic mutations can be sufficient by themselves to cause disease
(Mendelian), or can increase susceptibility to FSGS by potentiating the effects of environmental
factors.
The glomerulus is composed of three different cell types: endothelial cells, mesangial cells
and epithelial cells known as podocytes. The podocyte is an unusual cell that covers the outside
of the capillary wall and interdigitates with other podocytes to create small slits that allow the
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passage of fluid and small solutes into urinary space. It is now clear that podocyte dysfunction is
responsible for FSGS as well as other glomerular diseases such as minimal change disease,
membranous glomerulopathy and congenital nephrotic syndrome. Current models suggest that
increased podocyte loss is the primary lesion in FSGS [24, 26, 133, 134].
Over the last 10 years, highly penetrant disease genes has been identified in the fraction of
FSGS subjects with a family history [135–137]. However, they do not explain the majority of the
disease population, which are non-familial. In terms of number of people affected, the most
significant genetic contributor to FSGS susceptibility identified to date is APOL1. FSGS
associated alleles of APOL1, called G1 and G2, are common in West African populations,
possibly as a consequence of providing resistance to trypanosomiasis [19, 138, 139]. The
presence of two variant alleles significantly increases the risk of arterionephrosclerosis
(hypertensive nephropathy) (Odds Ratio (OR) = 7), FSGS (OR = 17) or HIV associated
nephropathy (OR = 29) in African [19, 20]. Approximately 13% of African Americans carry two
variant alleles and are at increased risk for chronic kidney disease. As these variants are absent
from individuals lacking any African ancestry, they are not documented to play a role in FSGS
susceptibility in other ancestries, and by themselves largely explain the increased frequency of
FSGS among African-Americans. Despite this, mechanisms by which APOL1 variants cause or
predispose to glomerular damage remain unknown.
Here, we used high-throughput sequencing of FSGS subjects to investigate whether
genetics plays a broader role in the majority of FSGS cases that cannot be explained by the
familial FSGS genes. Since FSGS is considered to be a disease of podocytes, we focused our
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sequencing analysis on 2500 genes that are highly and/or specifically expressed in podocytes.
DNA from 214 FSGS subjects including 192 sporadic cases and 22 familial cases were
sequenced (Table 4.1). DNA samples of FSGS subjects were mostly from a multi-center NIH
study of biopsy-confirmed FSGS [20], but also included some subjects diagnosed with FSGS by
kidney biopsy at Washington University. All subjects provided informed consent for genetic
studies. Control subjects sequenced for an autism study were used as controls [66]. Because the
controls were of European ancestry, we focused on FSGS subjects of similar genetic ancestry.
A major challenge of large scale sequencing studies will be to develop strategies that will
allow for candidate susceptibility genes identified through association studies to be
experimentally validated as functionally relevant to disease. Since there is no in vitro assay for
podocyte injury leading to FSGS, validating candidate genes here requires the use of an animal
model. We developed a system based on embryonic stem (ES) cells from a susceptible
background for FSGS that allows for efficient method for targeted delivery of shRNAs, and that
uses a method to generate mice that are close to 100% derived from the ES cells eliminating the
need for breeding. Scaling up our system will allow for large numbers of candidate genes
constituting the network of FSGS genes to be validated which will provide critical insight into the
pathogenesis of this disease syndrome.

In addition, our experimental approach should be

broadly applicable to studying other oligogenic diseases.

4.3 Methods
4.3.1 Exon capture and sequencing
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Sample preparation and sequencing were carried out using standard protocols for targeted
capture and Illumina sequencing. In brief, genomic DNA was fragmented to 150-200bp using a
Covaris E220 focused ultra-sonicator. The ends of the fragmented DNA were repaired using a
mixture of T4 DNA polymerase, Klenow polymerase and T4 polynucleotide kinase. Subsequently,
adapters for Illumina sequencing were ligated onto the fragments. These libraries were then
hybridized to biotinylated DNA probes from regions of interest (manufactured by MyGenostics,
Baltimore, MD). After washing away DNA libraries that bound non-specifically to the probes,
DNA of interest was recovered using Dynabeads® MyOne™ Streptavidin T1 (Life Technologies).
Resulting DNA libraries were amplified, if needed, to provide enough products for sequencing on
an Illumina HiSeq 2500.
4.3.2 Variant calling and data quality control
We performed alignment of the raw sequencing data and variant calling according to GATK
best practices with BWA/Picard/GATK software pipeline of the Broad Institute. To insure that we
are working with equally well-covered loci in both cases and controls we have performed a QC
separately on cases and controls genotypes applying following filters: (1) Keep only SNPs; (2)
Keep variants that PASS all GATK quality filters; (3) Keep genotypes with DP>10,GQ>30,AB for
hets 0.3<AB<0.7, for homozygous alternative AB<0.3; (4) Keep variants with less than 5% of
missing genotypes. After applying these filters we have combined variants from cases and
controls keeping only those variants with less than 5% of missing genotypes in both cases and
controls. Our final dataset contained 16108 SNPs in 1874 genes.
4.3.3 Principle component analysis and case-control matching
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PCA was performed with Eigenstrat software on the common (MAF>5%) variants found in
autosomes only. We computed a Euclidian distance from each point on the PCA plot to the origin
and plotted distributions of this parameter for both cases and controls. Using 3-sigma rule to
remove the samples that appeared to be outlying from the distribution. This resulted in 30
samples of mixed Hispanic ancestry to be removed from initial data.
Sample statistics and case-control matching metrics were computed using Plink-seq. We
have used number of variants called per sample, number of heterozygous genotypes per sample
and number of genotypes with minor allele per sample as a metrics representing genetic
background of the cohort. We established similarity between the genetic background of cases
and controls by matching mean and variance of case and control distributions for every metric.
We tested the validity of this approach by running Fisher’s exact test on the common variation
and QQ-plot of the p-values showed no inflation confirming absence of the population
stratification in the case-control dataset (Supplementary Figure 4.1).
4.3.4 Mouse strains and antibodies
Cd2ap+/- mice were generated in our previous study [77]. Synpo-/- mice were obtained from
Peter Mundel’s laboratory [140]. The Nphs1-rtTA3G (NEFTA) strain was a gift from Dr. Jeffrey
Miner’s laboratory [126]. Dlg5+/- strain was a gift from Dr. Valori Vasiokin’s lab [141]. All mouse
strains were genotyped by published protocol. All animal experiments were conducted with the
approval of the Washington University Animal Studies Committee.The antibodies used for
immunoblotting were mouse anti-XFP (632381; dilution, 1:10,000; Clontech), rabbit anti-ERK2
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(sc-154; dilution, 1:5,000; Santa Cruz Biotechnology), mouse anti-β-actin (A2228; dilution,
1:10000, Sigma), and rabbit anti-CD2AP (generated in our previous study, dilution, 1:10000)
4.3.5 Generation of a male Cd2ap+/-,Synpo+/-, NEFTA+ ES cell line
To generate a male ES cell line that was sensitized to FSGS, we bred Cd2ap+/-, Synpo-/males with NEFTA+ females. The females were superovulated using standard methods. After
mating, the embryos were isolated at the eight-cell stage (morulae), and cultured overnight in
KSOM (Millipore MR-121-D) micro-drops overlaid with mineral oil at 5% CO2 and 37C.
Blastocysts were transferred one per well, into 48 well plates with gamma-irradiated MEF
feeders and standard ESC Medium that contains 15% ES qualified fetal bovine serum
(SH30070.03E, Hyclone). The inner cell mass (ICM) was allowed to grow out. The ICM
outgrowth was trypsinized after 5-7 days depends on the size and shape of the outgrowth, and
cultured until ES colonies were identified. The colonies were expanded, frozen back and
genotyped by using standard methods.
4.3.6 Generation of miR30-shRNA knock-in transgenic mice
In our previous studies, we developed a method to integrate a single copy of transgene into
Hprt1 locus, and use 6-thioguanine to select for ES clones with homologous recombination [142].
Based on this method, we further developed a double selection method, which significantly
improve the chance of obtaining a positive ES clone.
A PGK-Puro cassette was inserted between the left and right arm of the pHPRT targeting
vector.

The

miR30-based

shRNA-expressing

transgene

that

was

driven

by

the

tetracycline-responsive promoter (TRE) was inserted between the left arm and the PGK-Puro
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cassette. Linearized targeting vector was transfected into ES cells that were growing at
extension phase. At 24 hours post transfection, the ES cells were treated by 1µg/mL puromycin
for 48 hours. Then the survived ES cells were passaged once. After 48 hours, the ES cells were
treated by 6-thioguanine for 48 hours. Survived ES cell colonies were picked, expanded, and
examined

by

genomic

PCR

across

the

5’-CAAGCCCGGTGCCTGATCTAGATCATAATC-3’;

right

arm

(Forward

Reverse

primer:
primer:

5'-CTGTAAAGGTCTCTGAACTACCAATTGCAC-3’). Positive ES cells were then stocked for
injection.
4.3.7 Laser assisted microinjection
The ES cells were maintained at extension phase before the injection. Eight ES cells were
injected into a recipient embryo at eight-cell stage by following a standard protocol published
previously [143]. Since the ES cell line produces mice with agouti coat color, albino B6
(C57BL/6J-Tyrc-2J) mice were used as host embryos for direct evaluation of chimerism by coat
color.
4.3.8 Cell culture and lentivirus infection
Immortalized murine podocytes were maintained and differentiated as described
previously [122]. To examine the knockdown efficiency of Cd2ap-sh877, podocytes were
infected with lentiviral vectors encoding miR30-sh877. A control lentiviral vector encoding
miR30-FF3 that targets fire fly luciferase cDNA was used as a control. The CD2AP expression
was examined by immunoblotting of the whole cell lysates.
4.3.9 Design and validation of the miR30-shRNA constructs for genes of interest
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The

shRNA

oligo

sequences

were

picked

using

an

online

algorism

(http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA) as described [144]. The miR30-shRNA
backbone

was

sub-cloned

by

PCR

from

pPRIME-CMV-GFP-FF3

(https://www.addgene.org/11663/) and inserted into pcDNA3.1-Zeo(+) vector to generate pcMIR
vector. To examine the knockdown efficiency, the miR30-shRNA construct and its artificial target
(Figure 4-S3B) were co-transfected into HEK293T cells at molar ratio 5:1. The expression of
EGFP in whole cell lysates was examined by immunoblotting.
4.3.10 Albumin-creatinine assay
Mouse urine samples were collected at the time points indicated in the figures, and urinary
albumin (E90-134; Bethyl) and creatinine (DICT-500; BioAssay Systems) were quantified by
enzyme-linked immunosorbent assays (ELISA) according to the manufacturers' protocols.
4.3.11 Transmission electron microscopy
Portions of kidney cortex were fixed with 2% paraformaldehyde and 2% glutaraldehyde.
Specimen processing, ultrathin sectioning, and imaging were performed by the Electron
Microscopy (EM) Core Facility at Washington University.

4.4 Results
4.4.1 Identification of podocyte genes for sequencing
To identify susceptibility genes for FSGS, we designed a custom exome capture reagent
that focused on genes that were highly expressed in podocytes and/or previously implicated in
FSGS. We began with five genes reported in OMIM in which heterozygous mutation confers risk
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to idiopathic FSGS: TRPC6 [17, 145], , INF2 [13], APOL1 [19], ACTN4 [8], and CD2AP (Kim et
al., 2003). Pathway analysis was performed to identify ~200 genes that are functionally linked to
known FSGS genes and other syndromic or recessive genes. 677 genes were added based on
their high expression in microdissected human glomeruli [147] and 1600 were the human
orthologs of the most highly expressed genes identified by DNA microarrays in mouse podocytes
[122, 148, 149]. Our total capture, which we term the “podocyte exome”, included about 2500
genes comprising a total of 7Mb. (Figure 4.1A).
4.4.2 Variant association analysis of FSGS patients of European ancestry using Next Generation
sequencing
DNA from 225 biopsy confirmed FSGS patients that were of European ancestry was
sequenced. Patient DNA samples were mostly from a multi-center NIH study of FSGS [150], but
also included some FSGS patients diagnosed at Washington University; all subjects provided
informed consent for genetic testing. The patient population included mostly sporadic but also
some cases of familial FSGS patients. Patients sequenced for an autism study, lacking
evaluation for kidney phenotypes were used as controls [66]. Because the controls were of
European ancestry, our plan was to focus on FSGS patients of similar genetic ancestry.

The

podocyte exome was captured from the FSGS patients and sequenced using standard
technologies with an average coverage of 200X.
Since the FSGS patient sequences were generated using a different platform and
sequenced at a different institution than were the controls, we needed to validate that the two
data sets were comparable as this is critical for unbiased analysis. After eliminating two case
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samples with <20x average coverage, data from all case and control samples were processed in
a single batch with raw data was aligned to the human genome using the BWA/Picard pipeline at
the Broad Institute and subsequent variant calling was performed using GATK Unified Genotyper
(Figure. 4.1B) [64, 151, 152].
The depth of coverage of protein coding exons targeted by both capture reagents was
compared between cases and controls; only those exons covered adequately (>20X) in both
cases and controls were advanced into the analysis stage. In summary, 16784 exons and
2769942 base pairs were confidently covered in both case and control cohorts, resulting in
16,008 SNPs and 1724 genes analyzed in the final dataset. The SNP calls were equally
represented in cases and controls (GQ>30 and rate of missing genotypes less than 5% in each
cohort) (Figure 4.1C).
Next, principal component analysis (PCA) was performed to define an appropriately
ancestry matched case-control sample set (Figure 4.2A,B). Thirty patient samples were removed
because a mixture of Hispanic ancestry was detected. Three more samples were removed
because the call-rate of SNPs was less than 95%. The number of SNPs, heterozygous
genotypes, and genotypes containing an alternative allele per sample were similar between
cases and controls. This reassured us that we could move forward with association analysis
(Figure

4.2C,D,E).

Our

final

dataset

contained

179

cases

and

378

controls

of

European-American ancestry as determined by PCA (Table 4.1). Accuracy of this analysis
strategy was further confirmed by resequencing key SNPs using Sanger sequencing.
4.4.3 Identification of new candidate genes by testing single variant associations
89

An association test examining single variants (minor allele frequency (MAF) >1%) was
performed using Fisher’s exact test. Ten common variants from nine different genes were
significantly enriched in cases versus controls with p-value < 0.001 and odds ratios > 4 (Table
4.2). These variants were found only in the sporadic cases and the controls. No common variant
was identified in the familial cases. Four cases carried a single copy of the APOL1 G1 variant
(G1); this allele is present in 29% of African Americans but only 0.03% of European Americans
and confers FSGS susceptibility when two APOL1 risk alleles are present [150]. A search of the
NHLBI-Exome Sequencing Project database showed that four other single variants enriched in
our cohort (WNK4, KANK1, IL36G, ARHGEF17) had MAFs that were more common in African
Americans. These variants were distributed across many patients, and no variant was linked to
other common African SNPs. The specific enrichment for African SNPs in some of our European
ancestry patients largely explains the high odds ratios that were calculated for these variants and
suggest that some of the risk variants could be ancestral variants.
4.4.4 Identification of new candidate genes by rare variant analysis
Rare variants (MAF < 1%) were analyzed by using tests that compare the total numbers of
rare variants between cases and controls. We used three such tests: the burden test [153], the
variable threshold test [154] and the C-alpha test [155]. Because the effect sizes of genetic
variants differ, the accuracy of each method can vary depending on the specific situation. Using
a p-value < 0.001 as a cutoff, we identified 11 genes as potential FSGS susceptibility genes
(Table 4.3): WNK4, APOL1, DLG5, GCC1, XYLT1, KAT2B, BPTF, COL4A4, NID1, EPHX1 and
EPHB6. Two of these genes, WNK4 and APOL1 were also identified by common variant analysis.
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In support of our approach, COL4A4, identified by rare variant analysis, was recently identified
as an FSGS susceptibility gene [156]. With the exception of APOL1 and COL4A4, none of the
identified genes has been previously identified as FSGS susceptibility genes. Thus, we identified
16 potential new FSGS genes.
4.4.5 Analysis of known familial FSGS genes
Family studies have identified about 20 genes as the cause of familial FSGS [157, 158]. To
determine, whether these genes are also involved in sporadic FSGS, we assessed the
frequencies of rare deleterious (missense/nonsense) coding variants in 20 of these genes in
cases and controls (Table 4.4). Among cases, 46/179 subjects (32%) had at least one rare
variant in these genes compared to 13/378 controls (3.4%, p value = 4.7e-14) (Table 4.1 and 4.5).
The distribution of variants between familial and sporadic cases was similar and consistent with
previous studies that about 30% of steroid resistant nephrotic syndrome cases have a variant in
a known disease gene [159]. There was also a difference in the total number of unique rare
variants identified in cases (59 variants in 179 cases) versus controls (15 variants in 378
controls). The significance of this finding was tested using a permutation analysis of groups of 20
genes randomly chosen from our dataset. This showed, however, that 27% of random sets of 20
genes had a p-value that was similar to or below 4.7e-14, suggesting the presence of novel
FSGS genes with strong genetic effects in our dataset.
4.4.6 Development of a sensitized mouse system to identify potential FSGS disease causing
genes
The FSGS syndrome likely involves diverse injury pathways and so no single in vitro
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system is available to test whether a particular gene variant might induce FSGS. We therefore
developed a genetic system in mouse, to examine the function of candidate genes in vivo in the
kidney. Our strategy involved knocking down the expression of candidate genes in a mouse
genetic background that is prone to develop FSGS. Previously, we showed that mice that are
heterozygous for two podocyte genes, Cd2ap and Synpo (encoding synaptopodin), developed
FSGS with an incomplete penetrance (~25%), with albuminuria, a sign of podocyte dysfunction
not apparent until animals are about six months of age [21]. We reasoned that if impairing the
function of a candidate gene worsened the phenotype on this transgenic background, by either
enhancing the penetrance or leading to an earlier onset of disease, it would validate the specific
candidate gene.
We generated ES cells from mice that were Cd2ap+/- Synpo+/- using standard methods
(Figure 4.3A). To induce RNAi expression in a podocyte specific fashion, the ES cells also
express a podocyte-specific and doxycycline-inducible trans-activator (Nphs1-rtTA3G) [126]. The
rtTA3G is a synthetic transcription factor that binds and transactivates promoters that contain the
bacterial tet-operator equence [160]. After confirming the genotype of the ES cells (Figure 4.3B),
we confirmed that the ES cells could generate mice with high-level chimerism using the
traditional method of blastocyst injection. Using the method of laser-assisted microinjection into
8-cell embryos [143], we also validated that these ES cells could generate mice that were close
to 100% derived from the ES cells as assessed by coat color (Figure 4.3C). As expected based
on the genotype (Huber et al., 2006), about 50% of the mice generated from these ES cells
developed mild proteinuria after three to four months of age (Figure 4.3D).
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We then used homologous recombination to integrate a single copy of the RNAi transgene
into the mouse Hprt1 locus to eliminate variability that could result from the random integration of
an RNAi transgene [142]. The Hprt1 locus is on the X chromosome and because the ES cells
were male, targeting of the transgene results in complete loss of the Hprt1 gene resulting in
resistance to 6-thioguanine (6-TG) toxicity (Figure 4.4A). This method was efficient as over 90%
of the ES cell colonies that survived selection had a correctly targeted recombination event (data
not shown).
We validated the system by testing an RNAi for Cd2ap. Mice that are Cd2ap+/- exhibit
normal renal function and have normal lifespans, but mice that completely lack Cd2ap
expression develop severe proteinuria shortly after birth [77]. To control shRNA expression by
doxycycline, shRNA oligos were embedded into the miR30 backbone that allows for RNA
polymerase II transcription [161]. We tested multiple Cd2ap specific RNAi’s in vitro for their ability
to inhibit Cd2ap expression (Figure 4.4B and 4.5A) and the best one (sh877) was targeted into
the Hprt1 locus of our ES cell line (Figure 4.5B). An RNAi targeting the firefly luciferase gene was
used as a control. Laser-assisted microinjection generated 16 animals that were nearly 100%
derived from the ES cell based on the completely agouti coat-color.
When the chimeric mice were two weeks of age, half were given doxycycline (DOX) in the
drinking water to induce shRNA transgene expression. Four weeks later, oodocyte function was
assessed by monitoring albumin leakage into the urine by measuring the ratio of albumin to
creatinine ratio. All of the DOX treated mice developed proteinuria with an average
albumin/creatinine ratio that was almost 150 fold higher than in the control animals
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(1.5 x 105

compared to 1.0 x 103) (Figure 4.4C). The proteinuria was sustained during eight weeks of DOX
treatment and was reversible, as proteinuria abated when DOX was removed (Figure 4.5D).
Histological analysis also confirmed the presence of proteinuria, as protein casts were
consistently present in tubules (Figure 4.4D). Electron microscopic examination of the kidney
showed widespread foot process effacement, another marker of proteinuria (Figure 4.4E).
Control RNAi mice targeting firefly luciferase showed no proteinuria after DOX treatment (Figure
4.4F). This verified that our RNAi strategy could be used to test candidate FSGS genes.
4.4.7 Testing candidate FSGS genes using the novel mouse genetic system
To validate our system, we chose four genes, WNK4, DLG5, ARHGEF17 and KANK1.
WNK4 was chosen as it was identified by single variant analysis and by all three rare variant
tests. ARHGEF17 and KANK1 were identified by single variant analysis but not by rare variant
analysis. DLG5 was identified by all three rare variant tests but not by single variant analysis.
Because the mouse ortholog for human KANK1 is unclear, we targeted Kank2 in addition to
Kank1.
Multiple shRNAs were generated for all five candidate genes and their efficacy was first
tested in vitro (Figure 4.6A, and 4.7A,B). Validated shRNAs were then ligated into targeting
constructs that were transfected into ES cells. After selection for loss of Hprt1, mice were
genotyped by PCR to confirm homologous recombination. Two independent clones for each
candidate gene were selected for microinjection and 15-30 mice were generated by
laser-assisted injection for each clone. Coat color verified that the chimerism for each animal was
close to 100%.
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At two weeks of age, half of each cohort was given DOX in the drinking water to induce
expression of the transgene. Proteinuria was assessed at four weeks and eight weeks after DOX
treatment, at which time mice were sacrificed for histological and electron microscopic
examination (Figure 4.6B~F). Induction of both the Wnk4, Arhgef17 and Kank2 RNAi transgenes
induced substantial proteinuria four weeks after induction with doxycycline with a level of
proteinuria that was between 150-200 fold higher than the controls. For both lines of mice,
proteinuria was attenuated after eight weeks (Figure 4.6B, D, E). The Kank1 RNAi mice showed
only modest proteinuria at the four-week time point but proteinuria increased significantly after
that (Figure 4.6C).
In contrast, Dlg5 RNAi mice did not develop significant proteinuria at any time up to 12
weeks after induction (Figure 4.6G and 4.7C). We validated this result by breeding Dlg5+/-mice to
our sensitized background (Cd2ap+/-, Synpo+/-). Up to six months of age, no significant difference
was detected between triple heterozygous mice (Dlg5+/-Cd2ap+/-, Synpo+/-) and double
heterozygous (Cd2ap+/-, Synpo+/-) littermates (Figure 4.6F). This suggested that Dlg5 is not an
FSGS susceptibility gene or that it may not be epistatic with Cd2ap and Synpo in podocytes. As
expected, electron microscopic examination of the kidneys showed podocyte foot process
effacement from Arhgef17 Kank1, Kank2 and Wnk4 RNAi mice, but not in Dlg5 RNAi mice
(Figure 4.7D).

4.5 Discussions
We added KANK1, WNK4 and ARHGEF17 to the list of 20 known FSGS genes and
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reanalyzed the differences between cases and controls. Addition of these three genes increased
the p-value to 1.6e-23. Testing random sets of 23 genes by permutation analysis in cases and
controls showed that only 0.04% of random sets equaled or matched the p-value for these 23
genes. This supports the idea that genetic variants in a specific subset of genes may function
more broadly to create a susceptible background for the development of sporadic FSGS.
The role of genetics in the pathogenesis of FSGS was thought to be restricted to those with
a family history. Familial studies have identified ~20 FSGS disease genes with specific variants
that are highly penetrant in these families. The identification of APOL1 as a sensitizing factor for
FSGS in African Americans with HIV demonstrated that genetic factors may also play a role in
enhancing susceptibility to FSGS by environmental factors [19, 20]. Here we found that DNA
variants in a set of 23 or more genes may play a role in over 46% of non-familial FSGS cases
presumably by enhancing podocyte susceptibility to injury. The role of genetics in sporadic cases
is likely much weaker than in the familial cases. Common variants were found exclusively in the
sporadic cases and in addition, a significant fraction of sporadic cases had more than one variant,
a feature that was not seen in any of the controls or the familial cases. Our analysis was likely
facilitated by our focus on podocyte-specific genes that we reasoned would have a higher
likelihood to be involved in FSGS and by our RNAi mouse model that allowed us to begin
validating these genes. Since oligogenic genetic effects and environmental factors are likely to
be broadly involved in disease susceptibility, our methods could be widely applicable to the study
of other rare and common diseases.
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4.6 Tables and Figures
Table 4.1 Distribution of single and rare variants in FSGS subjects and controls
A total of 192 sporadic and 22 familial FSGS cases were sequenced. 157 sporadic and 22
familial FSGS cases remained after quality control and were compared to 378 controls. The
number of subjects with predicted deleterious variants in 20 known FSGS genes, single variants
in the top 9 genes from the common variant analysis and the top 11 genes from rare variant
analyses. The total number of subjects with variants in 20 known FSGS genes + the three genes
that were validated are also shown.
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Table 4.2 Potential FSGS susceptibility genes identified by common variant analyses
15 potential susceptibility genes identified by common variant analysis.The frequency of
common variants (MAF > 1%) was assessed in cases versus controls and high scoring variants
with odds ratios greater than 2.5 are shown here ranked by p value. For each common variant,
the chromosome position, gene name, reference and alternative base pair, overall mean allele
frequency, number of alternative alleles in cases versus controls, total number of genotypes in
cases, the allele frequency in European vs African Americans from the ESP database, the p
value and the odds ratio and the Polyphen prediction score are shown.
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Table 4.3 Potential FSGS susceptibility genes identified by rare variant analyses
11 genes identified by rare variant analyses. Rare missense, and nonsense variants (MAF < 1%)
were pooled together for rare variant analysis using the burden, variable threshold and C-alpha
tests. The top genes (p-value < 0.001) identified for each test are shown ordered by p value.
Genes that were also identified by single gene analysis using Fisher’s exact test are shown in
bold.

Table 4.4 The list of 20 known FSGS genes
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Table 4.5 The list of rare deleterious variants identified in 20 known FSGS genes in the
FSGS subjects that we sequenced
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Figure 4.1 Comparability of variant calls between cases and controls
(A) Principal component analysis (PCA) of variants between cases (+) and controls (x) shows
close similarity of ancestry. (B) The PCA data shown in A is depicted as distance from the origin.
The 30 case sample with a distance of greater than 0.09 from the origin, suggesting substantial
admixture with non-European populations, were removed from further analysis. (C) The number
of total variants per sample were similar between cases and controls. (D) The number of
heterozygous (HET) genotypes was similar between cases and controls. (E) The number of
heterozygous or homozygous genotypes containing an alternative allele was similar between
cases and controls.
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Figure 4.2 Supplementary figure for Figure 4.1
(A) 2500 genes were clustered and defined as “podocyte exome”. (B) Average sequencing
coverage for all patients in FSGS cases. Each bar represents the coverage of a patient DNA
sample we sequenced. (C)PCA Plot. (D) Dapple analysis for the interaction network of all gene
identified by common and rare analyses.
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Figure 4.3 Generating an ES cell line with an FSGS susceptibility genetic background
(A) Male Synpo-/-, Cd2ap+/- and female Nphs1-rtTA3G mice were bred together to isolate
blastocyst. ES cell lines were derived from these blastocysts. The chance of deriving a male ES
cell line that is Synpo+/-, Cd2ap+/-, Nphs1-rtTA3G is 1/16. (B) Genomic PCR confirms B12 ES cell
line is male, Cd2ap+/- and Nphs1-rtTA3G. Synpo +/- was also confirmed (data not shown). (C)
Mice were generated using laser assisted injection from B12 ES cell line were monitored for the
development of proteinuria by measuring the urine albumin/creatinine ratio. Approximately 50%
of mice generated from these ES cells treated with or without doxycycline (administered from 2
weeks of age) slowly developed proteinuria over a period of 3-5 months.
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Figure 4.4 Generating a system to validate candidate FSGS genes
(A) The targeting strategy used to integrate a miR30-shRNA transgene into Hprt1 locus is shown.
A targeting vector with the miR30 transgene and a PGK-puromycin cassette was generated with
left and right homology arms containing sequences that flank exon1 of the Hprt1 gene on the X
chromosome. Primers (P1, P2, and P3) for PCR validation of homologous recombination are
shown. (B) The knockdown efficiency of a miR30 shRNA for Cd2ap (sh877) is shown. A
podocyte cell line was transduced with a lentivirus containing the Cd2ap shRNA was blotted for
Cd2ap expression. Erk2 was used as a protein loading control. Transduction with an shRNA
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targetting firefly luciferase (FF3) serves as a negative control. (C) Mice generated with ES cells
with the Cd2ap shRNA recombined in the Hprt1 locus were treated with and without doxycycline
for four or eight weeks and urine was analyzed by measuring the urine albumin/creatinine ratio.
(D) By light microscopy, Doxycycline treated Cd2ap-RNAi mice manifested proteinaceous
tubular casts (asterisks). (E) By electron microscopy, doxycycline dependent foot process
effacement was present in Cd2ap-RNAi mice, while podocyte cytoarchitecture is preserved in
control mice. (F) Control FF3-RNAi mice were treated with and without doxycycline for four and
eight weeks and urine analyzed by measuring the albumin/creatinine ratio.
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Figure 4.5 Supplemental figure for Figure 4.4
(A) The efficiency of 3 miR30-shRNAs that targets Cd2ap. A mouse CD2AP-EGFP construct
was co-expressed with different miR30-shRNA constructs in HEK293 cells. The expression level
of CD2AP-EGFP was detected by immunoblotting. Actin immunobltting was used as loading
control. FF3, A miR30-shRNA that targets fire fly luciferase was used as control. The design of
genomic PCR and the example of results that validate homologous recombination in ES clones.
Forward primer (P1: 5’-CAAGCCCGGTGCCTGATCTAG ATCATAATC-3’) was designed at the
end of puromycin resistant cassette. Two reverse primers were designed out side the Right Arm.
(P2:
5'-CTGTAAAGGTCTCTGAACTACCAATTGCAC-3',
and
P3:
5'-GAGACTAAGGCAGGAGGATTCCAGGTTTG -3'). (B) PCR validation of homologus
recombination. The arrows points the specific PCR products for the PCR reactions by using
P1+P2 and P1+P3, and the PCR products were confirmed by restriction digestion with desired
sizes of digested DNA fragements. (C) The system of podocyte-specific, DOX-inducible RNAi. (D)
Cd2ap-RNAi mice showed DOX-dependent proteinuria. The DOX treatment was stopped after 8
weeks. The urine samples were collected at 4, 8, 12 and 16-week time points. Albumin/creatinine
ratio was measured and plotted. (E) Untreated Cd2ap-RNAi mice showed normal foot
processes.
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Figure 4.6 Validation of five FSGS candidate disease genes
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(A) To select the best shRNA construct, multiple shRNAs were tested for Arhgef17, Dlg5, Kank1,
Kank2 and Wnk4 by inhibiting expression of a construct containing the GFP-tagged target
sequence in 293 cells (Figure 4-S3A). GFP immunoblotting was used to determine the best
shRNA for each gene. (B-E) Mice were generated by laser-assisted microinjection of ES cells
with the specific shRNAs for the indicated genes. After treatment with or without doxycycline to
induce expression of the transgene, urine albumin/creatinine ratio was measured after 4 and 8
weeks. As shown, shRNA knockdown of Arhgef17, Kank1, Kank2, and Wnk4 increased
proteinuria at 4 and 8 weeks, (F-G) By contrast, neither Dlg5 shRNA knockdown nor a
Dlg5+/-mouse on a susceptible genetic background (Cdap+/- and Synpo+/-) increased albuminuria.
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Figure 4.7 Supplemental figure for Figure 4.6
(A) The system was developed to test the RNAi efficiency of a given miR30-shRNA. The ExonX
targeted by the shRNA is amplified by genomic PCR and inserted to the 3’ end of EGFP
sequence of pEGFP-C1 vector. The pEGFP-C1-ExonX became an artificial target for the shRNA.
The pEGFP-C1-ExonX and miR30-shRNA constructs were co-expressed in 293 cells, and the
expression level of EGFP was detected by immuneblotting. (B) Immunoblotting results for each
miR30-shRNA oligo designed for the candidate genes. The FF3 miR30-shRNA was used as
control for each miR30-shRNA oligos. Actin immunoblotting was used as loading control. The
expression of EGFP was used as an indicator of the RNAi efficiency, the miR30-shRNA oligo
that had the best RNAi efficiency was inserted into pHPRT vector to generate RNAi ES cells and
mice. (C) Dlg5-RNAi mice showed no proteinuria after 12 weeks of DOX treatment. (D) Electron
microscopy of each RNAi mice showed the foot process effacement.
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Chapter 5. Conclusions and Future Directions

5.1 Conclusions
5.1.1 The balance between Rho and Rac activity maintains the morphology and function of the
podocyte.
To form properly interdigitated foot processes, podocytes established organized actin
cytoskeleton. In the foot processes, actin polymerize into at least two different structures that are
observed by transmission electron microscopy, the dense actin bundle and the loose cortical
actin network. In vitro, active Rho promotes the actin bundle formation, while active Rac
promotes the branched actin network. Podocytes regulate the spatial balance of Rac and Rho
activities. The active Rho could maintain the thick actin bundles along with other actin bundling
proteins such as alpha-actinin4 and INF2, while active Rac could keep the actin network next to
the silt diaphragm.
Over-active Rac or Rho in podocytes could cause transient or permanent damages.
Transgenic mice that express the constitutively active mutant of either Rac (CA-Rac) or Rho
(CA-Rho) are lethal in embryonic stage, which indicates the high toxicity of both constitutively
active mutants [162]. Inducible expression of CA-Rho in podocytes cause slow onset of
proteinuria and permanent FSGS [49]. In contrast, our research showed that inducible
expression of CA-Rac1 caused much faster onset of proteinuria, which can be detected as early
as 2 days post doxycycline treatment. This observation supports the hypothesis that foot process
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effacement is analogous to lamellipodia. Our result also supports that loss of podocyte foot
processes is a direct cause of albumin leakage. Long-term expression of CA-Rac1 could lead to
chronic damage such as glomerulosclerosis.
Podocytes express high level of ARHGAP24, a Rho-activated Rac/Cdc42 GAP. We
identified this gene initially by comparing expression profiles of differentiated versus
undifferentiated mouse podocytes, and later we found mutations of this gene associated with
familial FSGS. This protein is also called “FilGAP”, because it binds to filamin A, a protein that
dimerizes and binds to branched actin filaments [94, 114]. Thus, ARHGAP24 could work as a
barrier between the cortical actin network and the actin bundles to keep the active Rac from the
center of the foot processes.
5.1.2 The genetic susceptibility could explain over 46% of the non-familial FSGS subjects.
Our genetic study and podocyte-specific RNAi mouse model identified and validated
genetic susceptibility to FSGS in non-familial FSGS cases. FSGS was thought mainly caused by
environmental factors such as virus infection, and chemical toxins [3]. Studies of familial FSGS
cases have identified about 20 FSGS susceptibility genes, but only a few of them were recently
found mutated in non-familial cases. Here we identified another 16 genes that could potentially
involve in the susceptibility of non-familial FSGS. We validated 4 genes in our podocyte-specific
RNAi mouse model, ARHGEF17, KANK1, KANK2 and WNK4. We also observe that variants of
different genes presents in the same non-familial FSGS subjects but not in familial FSGS
subjects. This observation suggests that a combination of low penetrant genetic risks could
cause susceptibility to FSGS, which was first shown by our bigenic mouse models [21]. The
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oligogenic genetic factors of non-familial FSGS was not considered as important risk factors
before, but our research suggests that non-familial FSGS could caused by oligogenic genetic
factors plus an environmental trigger, such as virus infection, chemical toxicity, and a circulating
factor in the serum.
5.1.3 Actin Cytoskeleton pathway is the major pathway of susceptibility to FSGS.
Among the known FSGS genes and the susceptibility genes that we identified from our
sequencing approach, we found that a large proportion of these gene are involved in regulation
of actin cytoskeleton. In the 20 known FSGS genes (Table 4.4), 9 genes either directly interact
with actin filaments (INF2, ACTN4, MYO1E and CD2AP), or regulate the activity of Rho family
GTPases (ARHGAP24, ECT2, NPHS1, NPHS2, and TRPC6). 3 genes (COL4A3, COL4A4, and
LAMB2) are extracellular matrix genes that connect to intracellular actin network through
intergrins and focal complexes. Thus over half of the familial FSGS genes influence the actin
cytoskeleton. The secretion of extracellular matrix proteins is also regulated by actin
cytoskeleton. In the susceptibility genes we validated, 3 out of 4 regulate the actin through Rho
family GTPases, KANK1 [163], KANK2 [164] and ARHGEF17 [165]. The enrichment of mutants
in actin-associated and actin-regulatory genes in FSGS patients support the hypothesis the
natural susceptibility to FSGS comes from a weakly organized actin cytoskeleton in the
podocytes. Previous mouse model and human genetic studies also support this hypothesis.
Cd2ap deficient mice develop normal foot processes in the beginning and do not have any
protein leakge before 14 days of age. However, after 14 days post natal, Cd2ap deficient mice
start to exhibit foot process effacement and proteinuria. In children, NPHS2 mutations account
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for about 30% of steroid-resistant nephrotic syndrome [159], which also have proteinuria and foot
process effacement. These patients have normal kidney function and foot processes before the
syndrome starts. Thus the genetic lesion of NPHS2 might also lead to an actin network that is
susceptible to damage. Minimal change disease and steroid-sensitive nephrotic syndrome,
however, show transient proteinuria and foot process effacement, because the actin structure in
the podocytes could recover from the diseases to regenerate foot processes.
5.1.4 Elevated Rac signal could cause podocyte shattering and shattered podocytes could still
be functional to certain extent.
We detected EGFP_CA-Rac1+ podocytes in the urine of DOX induced NEFxRac1 mice.
Using intravital multi-photon microscopy (MPM), we observed that EGFP_CA-Rac1+ podocytes
enhanced membrane ruffling in the glomerulus and that some EGFP_CA-Rac1+ podocytes
attached to the renal tubules. These results indicate that abnormal activation of Rac in podocytes
could lead to increased membrane activity, deceased adherence, and podocyte loss.
Pathological changes that lead to Rac activation in podocytes could also initiate similar response.
At physiological condition, the crosstalk between podocytes and glomerular endothelial cells
could suppress the Rac activity, and could also maintain the normal foot process structure and
adherence. It is well studied that VEGF secreted by podocytes play an important role in
maintaining the endothelium, but which cytokine is maintaining low Rac in podocytes is still not
known. Damaging factors that increase Rac activity could compensate this physiological signal,
and could cause podocyte shattering into the urine.
The process that shattered podocyte established new interaction with the renal tubules
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after was overlooked before, because this event is very rare, and hard to detect by conventional
histological techniques. We uncovered this process by intravital MPM experiments. This
observation suggests that the defects caused by high Rac activity can be compensated and that
shattered podocytes are at least partially functional. How the Rac phenotype is compromised
and whether this process has physiological or pathological contribution are interesting questions
to answer.

5.2 Future Directions
5.2.1 The temporal change of Rho GTPase activity during podocyte damage.
Given the central role of Rho GTPase signaling in maintaining the normal actin
cytoskeleton structure in the podocyte, it is intriguing to know how small GTPases are activated
in different podocyte damage models. Do they share similar mechanism? Which GTPase
contribute the most to podocyte damage? Intravital imaging is a good approach to investigate
these questions. However, new mouse models with novel Rho GTPase sensors are required.
The bioluminence resonance energy transfer is a promising candidate sensor technique to
investigate dynamic singaling of small GTPases in vivo.
5.2.2 The function of ARHGEF17, KANK1, KANK2 and WNK4 in maintaining podocyte function.
In our sequencing study, we identified multiple candidate genes that could be potential
susceptibility gene and validated that decreased expression of ARHGEF17, KANK1, KANK2 and
WNK4 in podocytes could cause proteinuria in Cd2ap/Synpo double heterozygous background.
It remains unknown how these genes maintain normal podocyte function. Loss of function of
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these risk genes might not directly cause podocyte damage, and which environmental factor
trigger FSGS under these susceptible background is also an open question.
5.2.4 Can podocytes de-differentiate and become other cell types after they leave the
glomerulus?
Using intravital MPM imaging, we observed that podocytes could interact with other cells
outside the glomerulus. Is this phenomenon common in other models of podocyte damage? Are
these interactions transient? Can podocytes pass the tubular epithelium and enter the interstitial
space? Can they de-differentiate into mesenchymal cells? To answer these questions,
lineage-tracing experiments are required.
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